EP1682677B1 - Fragmentation enzymatique differentielle - Google Patents

Fragmentation enzymatique differentielle Download PDF

Info

Publication number
EP1682677B1
EP1682677B1 EP04796072A EP04796072A EP1682677B1 EP 1682677 B1 EP1682677 B1 EP 1682677B1 EP 04796072 A EP04796072 A EP 04796072A EP 04796072 A EP04796072 A EP 04796072A EP 1682677 B1 EP1682677 B1 EP 1682677B1
Authority
EP
European Patent Office
Prior art keywords
locus
methylation
dna
copies
intact
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP04796072A
Other languages
German (de)
English (en)
Other versions
EP1682677A4 (fr
EP1682677A2 (fr
Inventor
Jeffrey A. Jeddeloh
Nathan D. Lakey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Genomics LLC
Original Assignee
Orion Genomics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Genomics LLC filed Critical Orion Genomics LLC
Priority to EP10011859.5A priority Critical patent/EP2292795B1/fr
Publication of EP1682677A2 publication Critical patent/EP1682677A2/fr
Publication of EP1682677A4 publication Critical patent/EP1682677A4/fr
Application granted granted Critical
Publication of EP1682677B1 publication Critical patent/EP1682677B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification

Definitions

  • DNA typically comprises both methylated and unmethylated bases.
  • Prokaryotic DNA is methylated at cytosine and adenosine residues ( see, e.g., McClelland et al., Nuc. Acids. Res. 22:3640-3659 (1994 ).
  • Methylation of prokaryotic DNA protects the DNA from digestion by cognate restriction enzymes, i.e ., foreign DNAs (which are not methylated in this manner) that are introduced into the cell are degraded by restriction enzymes which cannot degrade the methylated prokaryotic DNA.
  • DNA methylation patterns can be used to identify specific bacterial types ( e.g ., genus, species, strains, and isolates)
  • Mammalian DNA can only be methylated at cytosine residues, typically these cytosines are 5' neighbors of guanine (CpG). This methylation has been shown by several lines of evidence to play a role in gene activity, cell differentiation, tumorigenesis, X-chromosome inactivation, genomic imprinting and other major biological processes ( Razin and Riggs eds. in DNA Methylation Biochemistry and Biological Significance, Springer-Verlag, N.Y., 1984 ).
  • methylation of cytosine residues that are immediately 5' to a guanosine occurs predominantly in CG poor loci ( Bird, Nature 321:209 (1986 )).
  • CpG islands discrete regions of CG dinucleotides called CpG islands remain unmethylated in normal cells, except during X-chromosome inactivation and parental specific imprinting ( Li, et al., Nature 366:362 (1993 )) where methylation of 5' regulatory regions can lead to transcriptional repression.
  • Aberrant methylation is often associated with a disease state.
  • de novo methylation of the Rb gene has been demonstrated in a small fraction of retinoblastomas ( Sakai, et al., Am. J. Hum. Genet., 48:880 (1991 )), and a more detailed analysis of the VHL gene showed aberrant methylation in a subset of sporadic renal cell carcinomas ( Herman, et al., PNAS USA, 91:9700 (1994 )).
  • Expression of a tumor suppressor gene can also be abolished by de novo DNA methylation of a normally unmethylated 5' CpG island.
  • Methylation changes at the insulin-like growth factor II/H 19 locus in kidney are associated with Wilms tumorigenesis. See, e.g ., Okamoto et al., PNAS USA 94:5367-5371 (1997 ).
  • the association of alteration of methylation in the p15, E-cadherin and von Hippel-Lindau loci are also associated with cancers. See, e.g ., Herman et al., PNAS USA 93:9821-9826 (1997 ).
  • the methylation state of GSTP1 is associated with prostrate cancer. See, e.g ., U.S. Patent No. 5,552,277 . Therefore, detection of altered methylation profiles at loci where such alterations are associated with disease can be used to provide diagnoses or prognoses of disease.
  • the present invention provides methods of detecting methylation at a locus within a population of nucleic acids using a methylation-dependent restriction enzyme and a methylation sensitive restriction enzyme, and optionally a methylation-insensitive restriction enzyme, as specified in the claims.
  • One embodiment of the invention provides a method of detecting the presence of methylation at a locus within a population of nucleic acids by (a) dividing the population of nucleic into at least four portions, (b) contacting a first portion with a methylation-sensitive restriction enzyme to obtain a population comprising fragmented unmethylated copies of the locus and intact methylated copies of the locus; (c) quantitatively amplifying the intact copies of the locus in the first portion; (d) contacting a second portion with a methylation-dependent restriction enzyme to obtain a population comprising fragmented methylated copies of the locus and intact unmethylated copies of the locus; (e) quantitatively amplifying the intact copies of the locus in the second portion; (f) determining the presence of methylation at the locus by comparing the number of intact copies of the locus in the first portion and number of intact copies of the locus in the second portion; (g) quantitatively amplifying a third portion of the nucleic acids, thereby ampl
  • the method may further comprise identification of mutations within the locus.
  • the method further comprises contacting a fifth portion of the nucleic acids with a methylation-insensitive restriction enzyme; quantitatively amplifying intact copies of the locus in the fifth portion to obtain a population of nucleic acids comprising a mutation at the locus; and determining the presence of a mutation at the locus by comparing the number of the intact copies of the locus in the fifth portion to the number of intact copies of the locus in the fourth portion and/or total intact copies of the locus in the third portion and/or intact copies of the locus in the first portion and/or intact copies of the locus in the second portion.
  • the number of unmethylated copies of the locus may be determined by subtracting the number of intact copies of the locus remaining after the first portion is cut with the methylation-sensitive restriction enzyme from the total intact copies of the locus.
  • the number of methylated copies of the locus may be determined by subtracting the number of intact copies of the locus remaining after the second portion is cut with the methylation-dependent restriction enzyme from the total intact copies of the locus.
  • the number of hemimethylated and mutant copies of the locus may be determined by (a) subtracting the number of intact copies of the locus remaining after the first portion is cut with the methylation-sensitive restriction enzyme from the total intact copies of the locus, thereby determining the number of unmethylated copies of the locus; and (b) subtracting the number of unmethylated copies of the locus from the number of intact copies of the locus remaining after the second portion is cut with the methylation-dependent restriction enzyme, thereby determining the number of hemimethylated and mutant copies of the locus.
  • the number of hemimethylated and mutant copies of the locus may be determined by: (a) subtracting the number of intact copies of the locus remaining after the second portion is cut with the methylation-dependent restriction enzyme from the total intact copies of the locus, thereby determining the number of methylated copies of the locus; and (b) subtracting the number of methylated copies of the locus from the number of intact copies of the locus remaining after the first portion is cut with the methylation-sensitive restriction enzyme, thereby determining the number of hemimethylated and mutant copies of the locus.
  • the number of methylated and unmethylated copies of the locus may be determined by subtracting the number of intact copies of the locus remaining after the fourth portion is cut with the methylation-dependent restriction enzyme and the methylation-sensitive restriction enzyme from the total intact copies of the locus, thereby determining the number of methylated and unmethylated copies of the locus.
  • the number of hemimethylated copies of the locus may be determined by subtracting the number of intact loci remaining after the fifth portion of the nucleic acids is contacted with a methylation-insensitive restriction enzyme from the number of intact copies of the locus remaining after the fourth portion is cut with the methylation-dependent restriction enzyme and the methylation-sensitive restriction enzyme.
  • the number of methylated copies of the locus may be determined by (a) subtracting the number of intact copies of the locus remaining after the fifth portion of the nucleic acids is contacted with a methylation-insensitive restriction enzyme from the number of intact copies of the locus remaining after the fourth portion is cut with the methylation-dependent restriction enzyme and the methylation-sensitive restriction enzyme, thereby determining the number of hemimethylated copies of the locus; and (b) subtracting the number of hemimethylated copies of the locus and the number of intact copies of the locus remaining after the fifth portion of the nucleic acids is contacted with the methylation-insensitive restriction enzyme from the number of intact copies of the locus remaining after the first portion of nucleic acids is contacted with the methylation-sensitive restriction enzyme, thereby determining the number of methylated copies of the locus.
  • the number of unmethylated copies of the locus may be determined by (a) subtracting the number of intact copies of the locus remaining after the fifth portion of the nucleic acids is contacted with a methylation-insensitive restriction enzyme from the number of intact copies of the locus remaining after the fourth portion is cut with the methylation-dependent restriction enzyme and the methylation-sensitive restriction enzyme, thereby determining the number of hemimethylated copies of the locus; and (b) subtracting the number of hemimethylated copies of the locus and the number of intact copies of the locus remaining after the fifth portion of the nucleic acids is contacted with the methylation-insensitive restriction enzyme from the number of intact copies of the locus remaining after the second portion of nucleic acids is contacted with the methylation-dependent restriction enzyme, thereby determining the number of umnethylated copies of the locus.
  • the quantifying steps may comprise the direct detection of intact copies of locus with hybrid capture.
  • the quantifying steps comprise quantitative amplification including, e.g. quantitative PCR.
  • the quantitative amplification product may be detected by detecting a label intercalated between bases of double stranded DNA sequences.
  • the quantitative amplification product may be detected by detecting hybridization of a detectably labeled oligonucleotide to the amplification product.
  • the detectably labeled oligonucleotide may be a labeled oligonucleotide probe comprising a fluorophore and a hairpin structure or a dual labeled oligonucleotide probe comprising a pair of interactive labels (e.g., a quencher and a fluorophore).
  • the fluorophore may be activated to generate a detectable signal when the probe hybridizes to its target nucleic acid sequence.
  • the fluorophore may be activated to generate a detectable signal when the probe hybridizes to its target nucleic acid sequence and an enzyme with 5' exonuclease activity cleaves the portion of the probe comprising the quencher.
  • the nucleic acids are contacted with an agent that modifies unmethylated cytosines before the amplification step; and the intact copies of the locus are amplified with a pair of oligonucleotide primers comprising at least one primer that distinguishes between modified methylated and unmethylated DNA.
  • the nucleic acids are contacted with an agent (e.g. sodium bisulfite) that modifies unmethylated cytosines before the amplification step; and the intact copies of the locus are amplified with a pair of oligonucleotide primers comprising at least one primer that distinguishes between the protected methylated and the modified unmethylated DNA.
  • an agent e.g. sodium bisulfite
  • the methylation-dependent restriction enzyme may be contacted to the second, third, or fourth portion under conditions that allow for at least some copies of potential restriction enzyme cleavage sites for the methylation-dependent restriction enzyme in the locus to remain uncleaved.
  • the density of methylation at the locus may be determined by comparing the number of intact methylated loci in the second, third, or fourth portion after cleavage with a control value representing the quantity of methylation in a control DNA.
  • the methylation-sensitive restriction enzyme may be contacted to the first or third portion under conditions that allow for at least some copies of potential restriction enzyme cleavage sites for the methylation-sensitive restriction enzyme in the locus to remain uncleaved.
  • the density of methylation at the locus may be determined by comparing the number of intact unmethylated loci in the first or third portion after cleavage with a control value representing the quantity of methylation in a control DNA.
  • the methylation may be at the C4 position of a cytosine, the C5 position of a cytosine within the locus, or at the N6 position of an adenosine within the locus.
  • the nucleic acids may be DNA, including, e.g genomic DNA.
  • the methylation-sensitive restriction enzyme may not cut when a cytosine within the recognition sequence is methylated at position C5.
  • the methylation-sensitive restriction enzyme may be Aat II, Aci I, Acl I, Age I, Alu I, Asc I, Ase I, Asi S I, Bbe I, Bsa A I, Bsa H I, Bsi E I, Bsi W I, Bsr F I, Bss H II, Bss K I, Bst B I, Bst N I, Bst U I, Cla I, Eae I, Eag I, Fau I, Fse I, Hha I, HinP 1 I, Hin C II, Hpa II, Hpy 99 I, Hpy CH4 IV, Kas I, Mbo I, Mlu I, Map Al I, Msp I, Nae I, Nar I, Not I, Pml I, Pst I, Pvu I, Rsr II, Sac 11, Sap 1, Sau 3A 1, Sfl 1, Sfo I, Sgr A I, Sma I, Sna B I, Tsc I, Xma I
  • the methylation-sensitive restriction enzyme may not cut when an adenosine within the recognition sequence is methylated at position N6.
  • the methylation-sensitive restriction enzyme may be Mho I.
  • the methylation-dependent restriction enzyme is Mcr BC, Mcr A, Mrr A, or Dpn I.
  • the first portion of genomic nucleic acids may be further contacted with at least a second methylation-sensitive restriction enzyme.
  • the second portion of genomic nucleic acids may be further contacted with at least a second methylation-dependent restriction enzyme.
  • the methylation-sensitive restriction enzyme may be methyl-adenosine sensitive.
  • the methylation-sensitive restriction enzyme may be methyl-cytosine sensitive.
  • the presence of methylation at the locus may be compared between at least two nucleic acid samples (e.g., isolated from at least two organisms having the same phenotype or a different phenotype).
  • the methods may comprise quantifying the intact methylated copies of the locus in a first sample and a second sample; and comparing the quantity of amplified products from the two samples, thereby determining relative methylation at the locus between the two samples.
  • a first nucleic acid sample may be isolated from a cell suspected of being a cancer cell and a second nucleic acid sample may be isolated from a non-cancerous cell.
  • the presence of methylation at two or more loci may be determined by quantitatively amplifying copies of intact DNA at the two different loci from a first portion contacted with a methylation-dependent restriction enzyme; quantitatively amplifying the intact DNA as the two loci from a second portion contacted with a methylation-sensitive restriction enzyme; and comparing the quantities of the amplified products for the two loci.
  • the population of nucleic acids may be isolated from a cell, including, e.g., a plant cell, a fungal cell, a prokaryotic cell, an animal cell, a mammalian cell, or a cancer cell.
  • the population of nucleic acids may be isolated from a sample from a subject (e.g., a human), including, e.g., a body fluid, a secretion, or a tissue biopsy.
  • a subject e.g., a human
  • the subject is suspected of having cancer.
  • the locus may comprise a sequence that is more methylated in diseased cells than in non-diseased cells.
  • the locus may comprise a sequence that is less methylated in diseased cells than in non-diseased cells.
  • the methods may further comprise adding sequence tags onto the ends of a population of nucleic acids before dividing the population of nucleic acids into equal portions, and step (c) comprises quantitatively amplifying the remaining intact methylated copies of the locus in the first portion with primers that initiate amplification from the sequence tags; and step (e) comprises quantifying the remaining unmethylated intact copies of the locus in the second portion with primers that initiate amplification from the sequence tags.
  • Figure 1 illustrates how the methods of the invention can be used to determine methylation at a locus.
  • Figure 2 illustrates results of amplification of DNA at different methylated: unmethylated dilutions.
  • Figure 3 illustrates the ability of Mcr BC to distinguish between DNA at different methylated: unmethylated dilutions.
  • the arrows at the bottom of the figure indicate the approximate ⁇ Ct between Hha I- cut and Hha I/ Mcr BC double cut samples.
  • Figure 4 illustrates analysis of DNA at a 1:2000 methylated:unmethylated dilution.
  • Figure 5 illustrates a plot of change in cycle threshold as a function of dilution of methylated/unmethylated DNA.
  • Figure 6 illustrates results from different methylated: unmethylated dilutions.
  • Figure 7 illustrates a hypothetical methylation density progression in the development of disease.
  • FIG. 8 illustrates Mcr BC DNA restriction.
  • Figure 9 illustrates amplification results from different Mcr BC dilutions restricting sparsely-methylated DNA.
  • Figure 10 illustrates amplification results from different McrBC dilutions restricting densely-methylated DNA.
  • Figure 11 illustrates using different restriction enzyme dilutions to determine optimum resolution between DNA with different methylation densities.
  • Figure 12 illustrates what data is obtained when the methylation state of only particular nucleotides is detected in a hypothetical disease progression.
  • Figure 13 illustrates what data is obtained when the average methylation density of a locus is detected in a hypothetical disease progression.
  • Figure 14 depicts a portion of the p16 promoter methylated in vitro with MSss I (SEQ ID NO:1)
  • Figure 15 illustrates data demonstrating that methylation-dependent (i.e ., McrBC ) and methylation-sensitive (i.e., ci I) restriction enzymes distinguish different methylation densities at a DNA locus.
  • Figure 16 illustrates cycle threshold data demonstrating that methylation-dependent (i.e ., McrBC ) and methylation-sensitive (i.e ., Aci I) restriction enzymes distinguish different methylation densities at a DNA locus.
  • Figure 17 illustrates a consensus restriction map of kanrin genes.
  • the relevant restriction sites are indicated vertically and the numbers indicate the distances scale in base-pairs.
  • Each coding sequence is depicted as the blue-shaded arrow, and the region assayed is indicated by the black bar.
  • the circles depict sites that are not present in every kafirin gene, and the color represents the number of genes that do not share the site.
  • the orange circle (5' most Hha I site) is conserved in 9 of 11 Kafirin genes, and the red circle (3' most Pst I site) is present in 10 of the 11.
  • Figure 18 illustrates the heterogenous CG methylation and homogenous CNG methylation of eleven kafirin genes.
  • the present invention provides methods of detecting the presence of methylation at a locus within a population of nucleic acids using methylation-sensitive restriction enzymes and methylation-dependent restriction enzymes, and optionally methylation-insensitive enzymes as specified in the claims.
  • nucleic acids comprising the locus of interest are cut with one or more restriction enzymes as described herein to generate populations of intact methylated loci, intact unmethylated loci, and/or intact hemimethylated loci.
  • the loci are amplified, and, the amplification products are compared. Comparison of the amplification products provides information regarding methylation at the locus.
  • DNA methylation plays important roles in gene regulation and therefore it is desirable to evaluate genomic methylation for numerous purposes. For example, the presence or absence of methylation at a particular locus can provide diagnostic and prognostic information regarding diseases associated with aberrant methylation at the locus.
  • Methods refers to cytosine methylation at C5 or N4 positions of cytosine ("5mC” and “4mC,” respectively), at the N6 position of adenine ("6mA”), or other types of nucleic acid methylation.
  • Aberrant methylation of a DNA sequence i.e. hypermethylation or hypomethylation
  • a disease, condition or phenotype e.g., cancer, vascular disease, cognitive disorders, or other epigenetic trait.
  • An "unmethylated" DNA sequence contains substantially no methylated residues at least at recognition sequences for a particular methylation-dependent or methylation-sensitive restriction enzyme used to evaluate the DNA.
  • Methods contains methylated residues at least at the recognition sequences for a particular methylation-dependent or methylation-sensitive restriction enzyme used to evaluate the DNA. It is understood that while a DNA sequence referred to as “unmethylated” may generally have substantially no methylated nucleotides along its entire length, the definition encompasses nucleic acid sequences that have methylated nucleotides at positions other than the recognition sequences for restriction enzymes. Likewise, it is understood that while a DNA sequence referred to as “methylated” may generally have methylated nucleotides along its entire length, the definition encompasses nucleic acid sequences that have unmethylated nucleotides at positions other than the recognition sequences for restriction enzymes. "Hemimethylated” DNA refers to double stranded DNA in which one strand of DNA is methylated at a particular locus and the other strand is unmethylated at that particular locus.
  • a "methylation-dependent restriction enzyme” refers to a restriction enzyme that cleaves at or near a methylated recognition sequence, but does not cleave at or near the same sequence when the recognition sequence is not methylated.
  • Methylation-dependent restriction enzymes include those that cut at a methylated recognition sequence (e.g., Dpn I) and enzymes that cut at a sequence that is not at the recognition sequence (e.g., Mcr BC).
  • McrBC requires two half-sites. Each half-site must be a purine followed by 5-methyl-cytosine (R5mC) and the two half-sites must be no closer than 20 base pairs and no farther than 4000 base pairs away from each other (N20-4000).
  • McrBC generally cuts close to one half-site or the other, but cleavage positions are typically distributed over several base pairs approximately 32 base pairs from the methylated base.
  • Exemplary methylation-dependent restriction enzymes include, e.g., Mcr BC (see, e.g., U.S. Patent No. 5,405,760 ), Mcr A, Mrr A, and Dpn I.
  • Mcr BC see, e.g., U.S. Patent No. 5,405,760
  • Mcr A Mrr A
  • Dpn I Dpn I.
  • a "methylation-sensitive restriction enzyme” refers to a restriction enzyme (e.g ., Pst I) that cleaves at or in proximity to an unmethylated recognition sequence but does not cleave at or in proximity to the same sequence when the recognition sequence is methylated.
  • a restriction enzyme e.g ., Pst I
  • Exemplary methylation sensitive restriction enzymes are described in, e.g., McClelland et al, Nucleic Acids Res. 22(17):3640-59 (1994 ) and http://rebase.neb.com.
  • Suitable methylation-sensitive restriction enzymes that do not cleave at or near their recognition sequence when a cytosine within the recognition sequence is methylated at position C 5 include, e.g., Aat II, Aci I, Acl I, Age I, Alu I, Asc I, Ase I, Asi S I, Bbe I, Bsa A I, Bsa H I, Bsi E I, Bsi W I, Bsr F I, Bss H II, Bss K I, Bst B I, Bst N I, Bst U I, Cla I, Eae I, Eag I, Fau I, Fse I, Hha I, Hin P1 I, Hin C II, Hpa II, Hpy 99 I, Hpy CH4 IV, Kas I, Mbo I, Mlu I, Map A1 I, Msp I, Nae I, Nar I, Not I, Pml I, Pst I, Pvu I, Rsr II, Sac II,
  • a methylation-sensitive restriction enzyme that fails to cut in the presence of methylation of a cytosine at or near its recognition sequence may be insensitive to the presence of methylation of an adenosine at or near its recognition sequence.
  • a methylation-sensitive restriction enzyme that fails to cut in the presence of methylation of an adenosine at or near its recognition sequence may be insensitive to the presence of methylation of a cytosine at or near its recognition sequence.
  • Sau3A I is sensitive ( i.e ., fails to cut) to the presence of a methylated cytosine at or near its recognition sequence, but is insensitive ( i.e ., cuts) to the presence of a methylated adenosine at or near its recognition sequence.
  • a methylation insensitive restriction enzyme refers to a restriction enzyme that cuts DNA regardless of the methylation state of the base of interest (A or C) at or near the recognition sequence of the enzyme.
  • a methylation-insensitive restriction enzyme that cuts in the presence of methylation of an adenosine at or near its recognition sequence, may be sensitive to the presence of methylation of a cytosine at or near its recognition sequence, i.e ., will fail to cut.
  • a methylation-insensitive restriction enzyme that cuts in the presence of methylation of a cytosine at or near its recognition sequence may be sensitive to the presence of methylation of an adenosine at or near its recognition sequence.
  • Sau3A I is insensitive (i.e ., cuts) to the presence of a methylated adenosine at or near its recognition sequence, but is sensitive ( i.e. , fails to cut) to the presence of a methylated cytosine at or near its recognition sequence.
  • Isoschizomers refer to distinct restriction enzymes have the same recognition sequence. As used in this definition, the "same recognition sequence” is not intended to differentiate between methylated and unmethylated sequences. Thus, an "isoschizomeric partner" of a methylation-dependent or methylation-sensitive restriction enzyme is a restriction enzyme that recognizes the same recognition sequence as the methylation-dependent or methylation-sensitive restriction enzyme regardless of whether a nucleotide in the recognition sequence is methylated.
  • a “recognition sequence” refers to a primary nucleic acid sequence and does not reflect the methylation status of the sequence.
  • methylation density refers to the number of methylated residues in a given locus of DNA divided by the total number of nucleotides in the same DNA sequence that are capable of being methylated. Methylation density is determined for cytosines only or adenosines only.
  • Divid in the context of dividing DNA, typically refers to dividing a population of nucleic acids isolated from a sample into two or more physically distinct portions, each of which comprise all of the sequences present in the sample. In some cases, "dividing” or “divided” refers to dividing a population of nucleic acids isolated from a sample into two or more physically distinct parts that do not contain all of the sequences present in the sample.
  • Cleaving DNA "under conditions that allow for at least some copies of potential restriction enzyme cleavage sites in the locus to remain uncleaved" refers to any combination of reaction conditions, restriction enzyme and enzyme concentration and/or DNA resulting in at least some of the DNA comprising a potential restriction enzyme cleavage site to remain uncut.
  • a partial digestion of the DNA e.g., by limiting the amount of enzyme or the amount of time of the digestion allows some potential restriction enzyme cleavage sites in the locus to remain uncut.
  • a complete digestion using a restriction enzyme such as McrBC will result in some potential restriction enzyme cleavage sites in the locus to remain uncut because the enzyme does not always cut between the two recognition half sites, thereby leaving at least some uncleaved copies of a locus in a population of sequences wherein the locus is defined by the two recognition half-sites.
  • a "potential restriction enzyme cleavage site” refers to a sequence that a restriction enzyme is capable of cleaving (i.e. comprising the appropriate nucleotide sequence and methylation status) when it recognizes the enzymes recognition sequence, which may be the same or different from the cleavage site.
  • a "partial digestion" of DNA as used herein refers to contacting DNA with a restriction enzyme under appropriate reaction conditions such that the restriction enzyme cleaves some (e.g., less than about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%) but not all of possible cleavage sites for that particular restriction enzyme in the DNA.
  • a partial digestion of the sequence can be achieved, e.g. by contacting DNA with an active restriction enzyme for a shorter period of time than is necessary to achieve a complete digestion and then terminating the reaction, by contacting DNA with less active restriction enzyme than is necessary to achieve complete digestion with a set time period (e.g., 30, 60, 90, 120, 150, 150, or 240 minutes), or under other altered reaction conditions that allow for the desired amount of partial digestion.
  • "Possible sites” are generally enzyme recognition sequences, but also include situations where an enzyme cleaves at a sequence other than the recognition sequence (e.g. Mcr BC).
  • Conditions including the time, buffers and other reagents necessary for complete digestions are typically provided by manufacturers of restriction enzymes. Those of skill in the art will recognize that the quality of the DNA sample may prevent complete digestion.
  • agent that modifies unmethylated cytosine refers to any agent that alters the chemical composition of unmethylated cytosine but does not change the chemical composition of methylated cytosine.
  • agents include sodium bisulfite, sodium metabisulfite, permanganate, and hydrazine.
  • Genomic DNA refers to the entire genomic sequence, or a part thereof, of an individual.
  • a “subset” of the genomic DNA refers to a part of the entire genomic sequence, i.e ., a subset contains only some, but not all of the loci of an entire genome.
  • the individual may be an animal, a plant, a fungus, or a prokaryote, as well as a cell, tissue, organ, or other part of an organism.
  • a “methylation profile” refers to a set of data representing the methylation state of DNA from e.g ., the genome of an individual or cells and tissues of an individual.
  • the profile can indicate the methylation state of every base pair in an individual or can comprise information regarding a subset of the base pairs ( e.g. , the methylation state of specific restriction enzyme recognition sequence) in a genome.
  • Amplification DNA refers to any chemical, including enzymatic, reaction that results in an increased number of copies of a template nucleic acid sequence or an increased signal indicating that the template nucleic acid is present in the sample.
  • Amplification reactions include polymerase chain reaction (PCR) and ligase chain reaction (LCR) (see U.S. Patents 4,683,195 and 4,683,202 ; PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS (Innis et al., eds, 1990 )), strand displacement amplification (SDA) ( Walker, et al. Nucleic Acids Res.
  • branched DNA signal amplification includes, e.g ., ligating adaptors that comprise T3 or T7 promoter sites to the template nucleic acid sequence and using T3 or T7 polymerases to amplify the template nucleic acid sequence.
  • locus refers to a target sequence within a population of nucleic acids (e.g., a genome). If a single copy of the target sequence is present in the genome, then “locus” will refer to a single locus. If multiple copies of the target sequence are present in the genome, then “locus” will refer to all loci that contain the target sequence in the genome.
  • Methods of the invention comprise comparing the presence or absence or amounts of intact DNA following restriction of a sample divided into at least four portions, wherein at least two portions are treated with different restriction enzymes.
  • a first portion is contacted with a methylation-dependent restriction enzyme (producing intact unmethylated DNA and fragmented methylated DNA) and a second portion is contacted with a methylation-sensitive restriction enzyme (producing intact methylated DNA and fragmented unmethylated DNA).
  • the intact copies of the locus from each portion are analyzed after the restriction digests and compared.
  • a third portion of nucleic acids comprising the locus is not digested with a restriction enzyme to provide an analysis of the total number of intact copies of a locus in a sample.
  • the total number of the intact copies of the locus can be compared to the number of methylated loci and/or the number of unmethylated loci to verify that the number of methylated loci and unmethylated loci are equal to the total number of loci.
  • a fourth portion of nucleic acids comprising the locus is digested with both the methylation-sensitive restriction enzyme and the methylation-dependent restriction enzyme and any intact loci are quantified (e.g., quantitatively amplified or detected by hybrid capture).
  • the total number of intact loci remaining after the double digestion can be compared to the number of methylated copies of the locus, unmethylated copies of the locus, and/or total copies of the locus to verify that the number of methylated copies and unmethylated copies are equal to the total number of copies and to verify that the cutting of the methylation sensitive and methylation dependent restriction enzymes is complete.
  • a fifth portion of nucleic acids comprising the locus may be digested with a methylation-insensitive restriction enzyme (i.e., either insensitive to methylation of an adenosine or of a cytosine residue at its recognition sequence) and any intact copies of the locus are detected.
  • a methylation-insensitive restriction enzyme i.e., either insensitive to methylation of an adenosine or of a cytosine residue at its recognition sequence
  • the total number of intact copies remaining after digestion can be compared to the number of methylated copies, unmethylated copies, and/or total copies to verify that the cutting of the other methylation sensitive and methylation dependent restriction enzymes is complete; and/or to identify mutations in copies of the locus that affect the recognition site of the methylation sensitive and methylation dependent restriction enzymes.
  • the samples are divided into equal portions, each of which contains all of the sequences present in the sample. In some cases, the samples may be divided into parts that do not contain all of the sequences present in the sample. However, by comparing results from different combinations of restriction digests, the number of methylated and unmethylated copies of the locus of interest can be determined. Any of the above populations can thus be compared to any other population. For example, populations (1) and (2) can be compared with one another, or either population (1) or (2) can be compared with another population, e.g. population (4).
  • the order in which the digest (s) are performed are not critical. Thus, although it may be preferable to perform a digest in a certain order, e.g., to first digest with a particular class of methylation-sensing enzymes, e.g., methylation-sensitive enzymes, it is not necessary. Similarly, it may be preferable to perform a double digest.
  • the nucleic acid may be obtained from a sample comprising a mixed population of members having different methylation profiles.
  • a biological sample may comprise at least one cell type with little or no methylation at a locus of interest and at least one cell type that is methylated at the locus.
  • the proportion of the population constituting methylated or unmethylated loci can be assessed by determining the amount of undigested loci in a single-digested aliquot treated with only methylation-sensitive or methylation-dependent restriction enzyme(s) to the amount of undigested DNA in an aliquot treated with both methylation-sensitive and methylation-dependent restriction enzymes.
  • a "single" digest may, in practice, be performed using more than one enzyme that is methylation-sensitive, or more than one enzyme that is methylation-dependent, whether used sequentially or simultaneously. For example, an aliquot that is digested with more than one methylation-sensitive restriction enzyme, but no methylation-dependent restriction enzymes is considered a "single” digest.
  • a "double" digest is considered to be an aliquot that has been treated using both methylation-sensitive and methylation-dependent restriction enzymes, whether used sequentially or simultaneously, regardless of the number of methylation-sensitive and methylation-dependent restriction enzymes employed.
  • the amount of undigested DNA in the single digest relative to the double digest and the total number of copies of the locus in the sample is indicative of the proportion of cells that contain unmethylated vs methylated DNA at the locus of interest. Furthermore, such an analysis can serve as a control for the efficacy of the single digest, e.g. the presence of a detectable change in the amount of undigested DNA in the double digest compared to the amount in the single digest with a methylation-sensitive restriction enzyme is an indication that the single digest went to completion.
  • the methods of the invention can be used to determine cytosine methylation or adenosine methylation at a particular locus based on, e.g ., the recognition sequence of the restriction enzyme.
  • a methylation-sensitive restriction enzyme which fails to cut when a methylated cytosine residue is in its recognition sequence (e.g., Hha I)
  • a methylation-dependent restriction enzyme which cuts only if its recognition sequence comprises a methylated cytosine (e.g ., Mcr BC)
  • adenosine methylation of a particular locus may be determined.
  • all four sets of digestions are conducted in parallel for both adenosine methylation and cytosine methylation to simultaneously determine the adenosine methylation and the cytosine methylation of a particular locus.
  • restriction enzymes that are either sensitive to methylated cytosine or to methylated adenosine can be used in the methods of the invention to provide populations of cytosine methylated loci and adenosine methylated loci for comparison.
  • Suitable methylation-dependent restriction enzymes include, e.g., Mcr BC, Mcr A, Mrr A , and Dpn I.
  • Suitable methylation-sensitive restriction enzymes include restriction enzymes that do not cut when a cytosine within the recognition sequence is methylated at position C 5 such as, e.g., Aat II, Aci I, Acl I, Age I, Alu I, Asc I, Ase I, AsiS I, Bbe I, Bsa A I, Bsa H I, Bsi E I, Bsi W I, Bsr F I, Bss H II, Bss K I, Bst B I, Bst N I, Bst U I, Cla I, Eae I, Eag I, Fau I, Fse I, Hha I, Hin P1 I, Hin C II, Hpa II, Hpy 99 I, Hpy CH4 IV, Kas I, Mlu I, Map A1 I , Msp I, Na
  • Suitable methylation-sensitive restriction enzymes include restriction enzymes that do not cut when an adenosine within the recognition sequence is methylated at position N 6 such as, e.g., Mbo I.
  • restriction enzymes that do not cut when an adenosine within the recognition sequence is methylated at position N 6 such as, e.g., Mbo I.
  • homologs and orthologs of the restriction enzymes described herein are also suitable for use in the present invention.
  • the nucleic acid portions are treated with an agent that modifies a particular unmethylated base, such as sodium bisulfite, prior to treatment with restriction enzymes.
  • the nucleic acids can then be treated and amplified using at least one primer that distinguishes between protected methylated and modified unmethylated nucleotides.
  • the amplified portions are then compared to determine relative methylation.
  • Certain quantitative amplification technologies employ one or more detection probes that are distinct from the amplification primers. These detection probes can also be designed to discriminate between protected methylated and modified unmethylated DNA.
  • This invention relies on routine techniques in the field of recombinant genetics. For example, methods of isolating genomic DNA, digesting DNA with restriction enzymes, ligating oligonucleotide sequences, detecting amplified and unamplified DNA, and sequencing nucleic acids are well known in the art. Basic texts disclosing the general methods of use in this invention include Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL (3rd ed. 2001 ); Kriegler, GENE TRANSFER AND EXPRESSION: A LABORATORY MANUAL (1990 ); and CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (Ausubel et al., eds., 2001 )).
  • Either partial or complete restriction enzyme digestions, depending on the restriction enzyme, can be used to provide information regarding the methylation density within a particular DNA locus.
  • the restriction enzymes for use in the invention are typically selected based on a sequence analysis of the locus of interest. One or more enzymes in each category (e.g ., methylation-dependent or methylation-sensitive) are then selected.
  • the sequence analysis can be performed based on evaluating databases of known sequences or in some instances, can be based on empirical determinations, e.g., to take into account variants such as mutations, that may be present in a particular subject.
  • DNA can be obtained from any biological sample can be used, e.g., from cells, tissues, and/or fluids from an organism (e.g. , an animal, plant, fungus, prokaryote).
  • the samples may be fresh, frozen, preserved in fixative (e.g., alcohol, formaldehyde, paraffin, or PreServeCyteTM) or diluted in a buffer.
  • fixative e.g., alcohol, formaldehyde, paraffin, or PreServeCyteTM
  • Bio samples include, e.g ., skin, blood or a fraction thereof, tissues, biopsies (from e.g ., lung, colon, breast, prostate, cervix, liver, kidney, brain, stomach, esophagus, uterus, testicle, skin, bone, kidney, heart, gall bladder, bladder, and the like), body fluids and secretions (e.g ., blood, urine, mucus, sputum, saliva, cervical smear specimens, marrow, feces, sweat, condensed breath, and the like).
  • Biological samples also include, leaves, stems, roots, seeds, petals, pollen, spore, mushroom caps, and sap.
  • a methylation sensing restriction enzyme i.e ., a methylation-dependent or methylation sensitive restriction enzyme
  • the information provided includes the presence or absence of methylation at recognition sequences of the restriction enzyme.
  • the presence of intact DNA in a locus comprising the cut site of the restriction enzyme indicates that the appropriate methylation state of the recognition site necessary for cleavage by the methylation-serisitive or methylation-dependent restriction enzyme was not present at or near the locus.
  • the amount of intact DNA can be compared to a control representing an equal amount of DNA from the sample that was not contacted with the restriction enzyme.
  • the amount of intact DNA at a locus can be compared to a second locus or to the same locus in DNA isolated from another cell.
  • the amount of intact DNA at a locus can be compared to DNA having a known or expected number of methylated and monitorable restriction sites. In some embodiments, the DNA being compared is approximately the same size. Those of skill in the art will appreciate that other controls are also possible. Thus, by detecting the amount of intact DNA at the locus following restriction enzyme digestion, the relative number of methylated alleles is determined.
  • Mcr BC Use of restriction enzymes that have a variable cleavage pattern near the recognition sequence (e.g., Mcr BC) provides a special case for complete digestions of DNA.
  • Mcr BC Use of restriction enzymes that have a variable cleavage pattern near the recognition sequence
  • McrBC DNA cutting occurs as follows. An eight subunit complex of Mcr B binds to each of two recognition half sites (purine-methylC represented as (A or G)mC). See Figure 8 . These complexes then recruit one McrC subunit to their respective half sites and start to translocate along the DNA mediated by GTP hydrolysis. When two Mcr BC bound complexes contact each other, a double-complex is formed and restriction occurs. Cutting will generally not occur if the two half sites are closer than 20bp and restriction resulting from half sites as far as 4kb from one another have been observed, though are rare.
  • Restriction may occur ⁇ 32 bp to the left or right of either bound half site, giving four possible cut site locations: ⁇ 32 bp 5' of the first half site, ⁇ 32 bp 3' of the first half site, ⁇ 32 bp 5' of the second half site, and ⁇ 32 bp 3' of the second half site. Therefore, it is possible for two half sites to exist within a locus defined by PCR primers and for cleavage to occur outside of the locus. It is also possible for two half sites to exist outside of the locus and for a cut to occur within the locus. It is also possible for one site to exist in the locus and for another to exist outside of the locus and for a cut to occur either within or outside of the locus.
  • the more methylated half sites that are "in the vicinity" of the locus (whether literally between the amplification primers or in neighboring flanking sequence), the more likely a cut will be observed within the locus for a given concentration of McrBC. Accordingly, the number of copies of a methylated locus that are cleaved by Mcr BC in a complete or partial digestion will be proportional to the density of methylated nucleotides.
  • the amount of cleavage with a methylation sensitive or methylation-dependent restriction enzyme in a partial (i.e., incomplete) digestion reflects not only the number of fragments that contain any DNA methylation at a locus, but also the average methylation density within the locus of DNA in the sample. For instance, when DNA fragments containing the locus have a higher methylation density, then a partial digestion using a methylation-dependent restriction enzyme will cleave these fragments more frequently within the locus. Similarly, when DNA fragments containing the locus have a lower methylation density, then a partial digestion using a methylation-dependent restriction enzyme will cleave these fragments less frequently within the locus, because fewer recognition sites are present.
  • DNA fragments with a higher methylated density are cleaved less, and thus more intact DNA strands containing the locus are present.
  • the digestion of DNA sample in question is compared to a control value such as those discussed above for complete digestions.
  • the DNA sample can be split into equal portions, wherein each portion is submitted to a different amount of partial digestion with Mcr BC or another methylation-dependent restriction enzyme.
  • the amount of intact locus in the various portions can be compared to a control population (either from the same sample representing uncut DNA or equivalent portions from another DNA sample).
  • the equivalent portions are from a second DNA sample
  • the second sample can have an expected or known number of methylated nucleotides (or at least methylated restriction enzyme recognition sequences) or, alternatively, the number of methylated recognition sequences can be unknown.
  • the control sample will often be from a sample of biological relevance, e.g., from a diseased or normal tissue, etc.
  • the DNA sample may be partially digested with one or more methylation-sensitive restriction enzymes and then amplified to identify intact loci. Controls in these cases are similar to those used for methylation-dependent restriction enzyme digestions described above. Untreated controls are undigested, and any treated control DNA samples are digested with methylation-sensitive restriction enzymes.
  • the conditions can be useful to test a variety of conditions (e.g., time of restriction, enzyme concentration, different buffers or other conditions that affect restriction) to identify the optimum set of conditions to resolve subtle or gross differences in methylation density among two or more samples.
  • the conditions may be determined for each sample analyzed or may be determined initially and then the same conditions may be applied to a number of different samples.
  • Control values can represent either external values (e.g., the number of intact loci in a second DNA sample with a known or expected number of methylated nucleotides or methylated restriction enzyme recognition sequences) or internal values (e.g., a second locus in the same DNA sample or the same locus in a second DNA sample). While helpful, it is not necessary to know how many nucleotides (i.e., the absolute value) in the control are methylated. For example, for loci in which methylation results in a disease state, knowledge that the locus is more methylated than it is in normal cells can indicate that the subject from which the sample was obtained may have the disease or be in the early stages of developing disease.
  • multiplex amplification e.g., multiplex PCR
  • two more loci e.g., at least one target locus and at least one control locus.
  • DNA samples can vary by two parameters with respect to methylation: (i) the percentage of total copies in a population that have any methylation at a specific locus, and (ii) for copies with any DNA methylation, the average methylation density among the copies. It is ideal, though not required, to use control DNAs that evaluate both of these parameters in a test sample.
  • Control DNAs with known methylated cytosines are produced using any number of DNA methylases, each of which can have a different target methylation recognition sequence. This procedure can create a population of DNA fragments that vary with respect to the methylation density (i.e., the number of methylated cytosines per allele). Partial methylase reactions can also be used, e.g., to produce a normally distributed population with a mode at the average methylation density for the population. The mode can be adjusted for a given population as a function of the completeness of the methylase reaction. Control DNAs can also be synthesized with methylated and unmethylated DNA bases.
  • a DNA target with a known sequence is used.
  • a desired control DNA can be produced by selecting the best combination ofmethylases and restriction enzymes for the analysis. First, a map of sites that can be methylated by each available methylase is generated. Second, a restriction map of the locus is also produced. Third, methylases are selected and are used to in vitro methylate the control DNA sample to bring about a desired methylation pattern, which is designed to perform optimally in combination with the restriction enzymes used in the methylation analysis of the test DNA and control DNA samples. For example, M . Hha I methylates the site (G*CGC) and Mcr BC recognizes two half sites with the motif (RpC). Therefore, each methylated M.Hha I site in the control sequence is recognized by McrBC.
  • a population of molecules may be then treated with a DNA methylase (e.g . , MSss I) in the presence of magnesium to result in a desired methylation density. If the reaction is allowed to run to completion, nearly all of the sites that can be methylated will be methylated, resulting in a high and homogeneous methylation density. If the reaction is limited in its course, a lower average methylation density (or partial methylation) will result (i.e. , all possible sites are not methylated due to timing of reaction and/or concentration of enzyme). In this way, the desired average methylation density of the control DNA can be produced.
  • a DNA methylase e.g . , MSss I
  • the methylated control DNA can be precisely characterized by determining the number of methylated cytosines through bisulfite sequencing.
  • the methylation control DNA can be precisely characterized by determining the number of methylated cytosines through a comparison to other known control DNAs as described herein.
  • a control set of DNA that can conveniently serve as a standard curve where each sample in the control set has a different methylation density, either known or unknown.
  • a standard curve of the amount of intact copies e.g. , represented by Ct values
  • the standard curve can then be used to determine the methylation density of a test DNA sample by interpolating the amount of intact DNA in the sample following restriction and amplification as described herein.
  • cycle thresholds are a useful measurement for determining the initial amount of DNA template in an amplification reaction. Accordingly, Ct values from samples treated with a methylation-dependent and/or methylation-sensitive restriction enzyme and amplified as described herein can be used to calculate methylation density. A change in Ct value between one sample and a control value (which can represent the Ct value from a second sample) is predictive of relative methylation density. Because amplification in PCR theoretically doubles copies every cycle, 2 x is proportional to the number of copies in the amplification during exponential amplification, where X is the number of cycles. Thus 2 Ct is proportional to the amount of intact DNA at the initiation of amplification.
  • the change of Ct ( ⁇ Ct) between two samples or between a sample and a control value represents the difference in initial starting template in the samples. Therefore, 2
  • is proportional to the relative methylation density difference between a sample and a control or a second sample. For instance, a difference of 1.46 in the Ct between two samples (each treated with a methylation-dependent restriction enzyme and subsequently amplified) indicates that one sample has approximately 2.75 (i.e., 2 (146) 2.75) times more methylated nucleotides within the monitored sites at a locus than the other sample.
  • the presence and quantity of DNA cleaved by the restriction enzymes can be detected using any means known in the art including, e.g., quantitative amplification, hybrid capture, or combinations thereof.
  • the presence and quantity of DNA cleaved by the restriction enzymes can be determined by amplifying the locus following digestion.
  • amplification techniques e.g., the polymerase chain reaction (PCR)
  • PCR reactions can be designed in which the amplification primers flank a particular locus of interest. Amplification occurs when the locus comprising the two primers remains intact following a restriction digestion. If the amount of total and intact DNA is known, the amount of cleaved DNA can be determined. Since cleavage of the DNA depends on the methylation state of the DNA, the intact and cleaved DNA represents different methylation states.
  • Amplification of a DNA locus using reactions is well known (see U.S. Patents 4,683,195 and 4,683,202 ; PCR PROTOCOLS: A GUIDE TO METHOD AND APPLICATIONS (Innis et al., eds, 1990 )).
  • PCR is used to amplify DNA templates.
  • alternative methods of amplification have been described and can also be employed, as long as the alternative methods amplify intact DNA to a greater extent than the methods amplify cleaved DNA.
  • DNA amplified by the methods of the invention can be further evaluated, detected, cloned, sequenced, and the like, either in solution or after binding to a solid support, by any method usually applied to the detection of a specific DNA sequence such as PCR, oligomer restriction ( Saiki, et al., Bio/Technology 3:1008-1012 (1985 )), allele-specific oligonucleotide (ASO) probe analysis ( Conner, et al., PNAS USA 80:278 (1983 )), oligonucleotide ligation assays (OLAs) ( Landegren, et al., Science 241:1077, (1988 )), and the like. Molecular techniques for DNA analysis have been reviewed ( Landegren, et al., Science 242:229-237 (1988 )).
  • Quantitative amplification methods can be used to quantify the amount of intact DNA within a locus flanked by amplification primers following restriction digestion.
  • Methods of quantitative amplification are disclosed in, e.g., U.S. Patent Nos. 6,180,349 ; 6,033,854 ; and 5,972,602 , as well as in, e.g. , Gibson et al., Genome Research 6:995-1001 (1996 ); DeGraves, et al., Biotechniques 34(1):106-10,112-5 (2003 ); Deiman B, et al., Mol Biotechnol. 20(2):163-79 (2002 ). Amplifications may be monitored in "real time.”
  • amplification is based on the monitoring of the signal (e.g. , fluorescence of a probe) representing copies of the template in cycles of an amplification (e.g. , PCR) reaction.
  • the signal e.g. , fluorescence of a probe
  • an amplification e.g. , PCR
  • a very low signal is observed because the quantity of the amplicon formed does not support a measurable signal output from the assay.
  • the signal intensity increases to a measurable level and reaches a plateau in later cycles when the PCR enters into a non-logarithmic phase.
  • the specific cycle at which a measurable signal is obtained from the PCR reaction can be deduced and used to back-calculate the quantity of the target before the start of the PCR.
  • the number of the specific cycles that is determined by this method is typically referred to as the cycle threshold (Ct).
  • Ct cycle threshold
  • Exemplary methods are described in, e.g. , Heid et al. Genome Methods 6:986-94 (1996 ) with reference to hydrolysis probes.
  • the fluorogenic probe consists of an oligonucleotide labeled with both a fluorescent reporter dye and a quencher dye. During PCR, this probe is cleaved by the 5'-exonuclease activity of DNA polymerase if, and only if, it hybridizes to the segment being amplified. Cleavage of the probe generates an increase in the fluorescence intensity of the reporter dye.
  • Another method of detecting amplification products that relies on the use of energy transfer is the "beacon probe” method described by Tyagi and Kramer, Nature Biotech. 14:303-309 (1996 ), which is also the subject of U.S. Patent Nos. 5,119,801 and 5,312,728 .
  • This method employs oligonucleotide hybridization probes that can form hairpin structures. On one end of the hybridization probe (either the 5' or 3' end), there is a donor fluorophore, and on the other end, an acceptor moiety. In the case of the Tyagi and Kramer method, this acceptor moiety is a quencher, that is, the acceptor absorbs energy released by the donor, but then does not itself fluoresce.
  • the molecular beacon probe which hybridizes to one of the strands of the PCR product, is in the open conformation and fluorescence is detected, while those that remain unhybridized will not fluoresce ( Tyagi and Kramer, Nature Biotechnol. 14: 303-306 (1996 )).
  • the amount of fluorescence will increase as the amount of PCR product increases, and thus may be used as a measure of the progress of the PCR.
  • some methodologies employ one or more probe oligonucleotides that are structured such that a change in fluorescence is generated when the oligonucleotide(s) is hybridized to a target nucleic acid.
  • one such method involves is a dual fluorophore approach that exploits fluorescence resonance energy transfer (FRET), e.g., LightCyclerTM hybridization probes, where two oligo probes anneal to the amplicon.
  • FRET fluorescence resonance energy transfer
  • the oligonucleotides are designed to hybridize in a head-to-tail orientation with the fluorophores separated at a distance that is compatible with efficient energy transfer.
  • ScorpionsTM probes e.g., Whitcombe et al., Nature Biotechnology 17: 804-807, 1999 , and U.S. Pat. No. 6,326,145
  • SunriseTM or AmplifluorTM
  • Intercalating agents that produce a signal when intercalated in double stranded DNA may be used.
  • exemplary agents include SYBR GREENTM and SYBR GOLDTM. Since these agents are not template-specific, it is assumed that the signal is generated based on template-specific amplification. This can be confirmed by monitoring signal as a function of temperature because melting point of template sequences will generally be much higher than, for example, primer-dimers, etc.
  • Methylation-specific PCR can be employed to monitor the methylation state of specific nucleotides in a DNA locus.
  • the DNA is combined with an agent that modifies unmethylated cytosines. For example, sodium bisulfite is added to the DNA, thereby converting unmethylated cytosines to uracil, leaving the methylated cytosines intact.
  • an agent that modifies unmethylated cytosines For example, sodium bisulfite is added to the DNA, thereby converting unmethylated cytosines to uracil, leaving the methylated cytosines intact.
  • One or more primers are designed to distinguish between the methylated and unmethylated sequences that have been treated with sodium bisulfite.
  • primers complementary to the bisulfite-treated methylated sequence will contain guanosines, which are complementary to endogenous cytosines.
  • Primers complementary to the bisulfite-treated unmethylated sequence will contain adenosine, which are complementary to the uracil, the conversion product of unmethylated cytosine.
  • nucleotides that distinguish between the converted methylated and unmethylated sequences will be at or near the 3' end of the primers. Variations of methods using sodium bisulfite-based PCR are described in, e.g., Herman et al., PNAS USA 93: 9821-9826 (1996 ); U.S. Patent Nos. 5,786,146 and 6,200,756 .
  • Nucleic acid hybrid capture assays can be used to detect the presence and quantity of DNA cleaved by the restriction enzymes. This method can be used with or without amplifying the DNA. Following the restriction digests, RNA probes which specifically hybridize to DNA sequences of interest are combined with the DNA to form RNA:DNA hybrids. Antibodies that bind to RNA:DNA hybrids are then used to detect the presence of the hybrids and therefore, the presence and amount of uncut DNA. DNA fragments that are restricted in a window of sequence that is complimentary to the RNA probe hybridize less efficiently to the RNA probe than do DNA fragments that remain intact in the window of sequence being monitored. The amount of hybridization allows one to quantify intact DNA, and the quantity of DNA methylation can be inferred directly from the quantity of intact DNA from different restriction enzyme treatments (i.e. methylation-sensitive and/or methylation-dependent restriction enzyme treatments).
  • RNA:DNA hybrids using antibodies are known in the art and are described in, e.g., Van Der Pol et al., J. Clin. Microbiol. 40(10): 3558 (2002 ); Federschneider et al., Am. J. Obstet. Gynecol. 191(3):757 (2004 ); Pretet et al., J. Clin. Virol. 31(2): 140-7 (2004 ); Giovannelli et al., J. Clin. Microbiol. 42(8): 3861 (2004 ); Masumoto et al., Gynecol. Oncol. 94(2): 509-14 (2004 ); Nonogaki et al., Acta Cytol.
  • the antibodies are labeled with a detectable label (e.g., an enzymatic label, an isotope, or a fluorescent label) to facilitate detection.
  • a detectable label e.g., an enzymatic label, an isotope, or a fluorescent label
  • the antibody:nucleic acid complex may be further contacted with a secondary antibody labeled with a detectable label.
  • suitable immunological and immunoassay procedures see, e.g. Harlow & Lane, ANTIBODIES, A LABORATORY MANUAL, Cold Spring Harbor Publication, New York (1988 ); Basic and Clinical Immunology (Stites & Terr eds., 7th ed. 1991 ); U.S. Patents 4,366,241 ; 4,376,110 ; 4,517,288 ; and 4,837,168 ); Methods in Cell Biology: Antibodies in Cell Biology, volume 37 (Asai, ed. 1993 ).
  • Monoclonal, polyclonal antibodies, or mixtures thereof may be used to bind the RNA:DNA hybrids. Detection of RNA:DNA hybrids using monoclonal antibodies is described in, e.g., U.S. Patent Nos. 4,732,847 and 4,833,084 . Detection ofRNA:DNA hybrids using polyclonal antibodies is described in, e.g., U.S. Patent No. 6,686,151 .
  • the polyclonal or monoclonal antibodies may be generated with specific binding properties. For example, monoclonal or polyclonal antibodies that specifically bind to shorter (e.g., less than 20 base pairs) or longer (e.g., more than 100 base pairs) RNA:DNA hybrids may be generated. In addition, monoclonal or polyclonal antibodies may be produced that are either more or less sensitive to mismatches within the RNA:DNA hybrid.
  • RNA:DNA hybrids Methods of producing polyclonal and monoclonal antibodies that react specifically with RNA:DNA hybrids are known to those of skill in the art. For example, preparation of polyclonal and monoclonal antibodies by immunizing suitable laboratory animals (e.g., chickens, mice, rabbits, rats, goats, horses, and the like) with an appropriate immunogen (e.g., an RNA:DNA hybrid). Such methods are described in, e.g., Coligan, Current Protocols in Immunology (1991 ); Harlow & Lane, supra; Goding, Monoclonal Antibodies: Principles and Practice (2d ed. 1986 ); and Kohler & Milstein, Nature 256: 495-497 (1975 ).
  • suitable laboratory animals e.g., chickens, mice, rabbits, rats, goats, horses, and the like
  • an appropriate immunogen e.g., an RNA:DNA hybrid
  • Antibodies can also be recombinantly produced. Antibody preparation by selection of antibodies from libraries of nucleic acids encoding recombinant antibodies packaged in phage or similar vectors is described in, e.g., Huse et al., Science 246: 1275-1281 (1989 ) and Ward et al., Nature 341: 544-546 (1989 ). In addition, antibodies can be produced recombinantly using methods known in the art and described in, e.g., Sambrook et al., Molecular Cloning, A Laboratory Manual (2nd ed. 1989 ); Kriegler, Gene Transfer and Expression: A Laboratory Manual (1990 ); and Current Protocols in Molecular Biology (Ausubel et al., eds., 1994 )).
  • the methods of the invention can be used to determine the methylation density of a locus. Determination of methylation density is described, e.g., in U.S. Patent Application No. 60/513,426, filed October 21, 2003 .
  • the quantity of methylation of a locus of DNA can be determined by providing a sample of genomic DNA comprising the locus, cleaving the DNA with a, restriction enzyme that is either methylation-sensitive or methylation-dependent, and then quantifying the amount of intact DNA or quantifying the amount of cut DNA at the DNA locus of interest.
  • the amount of intact or cut DNA will depend on the initial amount of genomic DNA containing the locus, the amount of methylation in the locus, and the number ( i.e. , the fraction) of nucleotides in the locus that are methylated in the genomic DNA.
  • the amount of methylation in a DNA locus can be determined by comparing the quantity of intact or cut DNA to a control value representing the quantity of intact or cut DNA in a similarly-treated DNA sample.
  • the control value can represent a known or predicted number of methylated nucleotides.
  • the control value can represent the quantity of intact or cut DNA from the same locus in another (e.g. , normal, non-diseased) cell or a second locus.
  • average methylation density of a locus may be determined. If the methylation-sensitive restriction enzyme is contacted to copies of a DNA locus under conditions that allow for at least some copies of potential restriction enzyme cleavage sites in the locus to remain uncleaved, then the remaining intact DNA will be directly proportional to the methylation density, and thus may be compared to a control to determine the relative methylation density of the locus in the sample.
  • a methylation-dependent restriction enzyme is contacted to copies of a DNA locus under conditions that allow for at least some copies of potential restriction enzyme cleavage sites in the locus to remain uncleaved, then the remaining intact DNA will be inversely proportional to the methylation density, and thus may be compared to a control to determine the relative methylation density of the locus in the sample.
  • the average methylation density within a locus in a DNA sample is determined by digesting the DNA with a methylation-sensitive or methylation-dependent restriction enzyme and quantifying the relative amount of remaining intact DNA compared to a DNA sample comprising a known amount of methylated DNA.
  • partial digestions or complete digestions can be used. As described above for uniformly methylated DNA, use of partial digestions allows for the determination of the average methylation density of the locus.
  • the methods of the invention can be used to detect differences in methylation between nucleic acid samples (e.g., DNA or genomic DNA) and/or at specific loci.
  • the methods can be used to analyze a sample of DNA where all copies of a genomic DNA locus have an identical methylation pattern.
  • the DNA sample may be a mixture of DNA comprising alleles of a DNA locus in which some alleles are more methylated than others.
  • a DNA sample may contain DNA from two or more different cell types, wherein each cell type has a different methylation density at a particular locus (e.g., a cell from a tissue suspected of being diseased and a cell from a non-diseased tissue sample).
  • neoplastic cells have different methylation densities compared to normal cells.
  • a tissue, body fluid, or secretion contains DNA from both normal and neoplastic cells
  • the DNA sample from the tissue, body fluid, or secretion will comprise a heterogeneous mixture of differentially methylated alleles.
  • one set of alleles within the DNA e.g., those derived from neoplastic cells in the sample
  • will have a different methylation density than the other set of alleles e.g., those derived from normal cells).
  • DNA samples should be prepared from a tissue of interest, or as appropriate, from blood.
  • DNA can be prepared from biopsy tissue to detect the methylation state of a particular locus associated with cancer.
  • the nucleic acid-containing specimen used for detection of methylated loci may be from any source including brain, colon, urogenital, hematopoietic, thymus, testis, ovarian, uterine, prostate, breast, colon, lung and renal tissue and may be extracted by a variety of techniques such as that described by Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (1995 ) or Sambrook et al., MOLECULAR CLONING, A LABORATORY MANUAL (3rd ed. 2001 ).
  • Detection and identification of loci of altered methylation (compared to normal cells) in DNA samples can indicate that at least some of the cells from which the sample was derived are diseased.
  • diseases include but are not limited to, e.g., low grade astrocytoma, anaplastic astrocytoma, glioblastoma, medulloblastoma, colon cancer, liver cancer, lung cancer, renal cancer, leukemia (e.g., acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia), lymphoma, breast cancer, prostate cancer, cervical cancer, endometrial cancer, neuroblastoma, cancer of the oral cavity (e.g.
  • stomach cancer cancer
  • small intestine rectal cancer
  • anal cancer cancer of the anal canal and anorectum
  • cancer of the intrahepatic bile duct gallbladder cancer
  • biliary cancer pancreatic cancer
  • bone cancer cancer of the joints
  • skin cancer e.g.
  • melanoma non-epithelial cancer, basal cell carcinoma, squamous cell carcinoma), soft tissue cancers, uterine cancer, ovarian cancer, vulval cancer, vaginal cancer, urinary cancer, cancer of the ureter, cancer of the eye, head and neck cancer, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, brain cancer, cancer of the nervous system. Identification of altered methylation profiles is also useful for detection and diagnosis of loss of genomic imprinting, fragile X syndrome and X-chromosome inactivation.
  • Table 1 Examples of Genes Exhibiting Hypermethylation in cancer Gene Effect of loss of function in tumor development Tumor types RB Loss of cell-cycle control Retinoblastoma MLH1 Increased mutation rate, drug resistance Colon, ovarian, endometrial, gastric BRCA1 Genomic instability Breast, ovarian E-CAD Increased cell motility Breast, gastric, lung, prostate, colon, leukemia APC Aberrant cell transduction Breast, lung, colon, gastric, esophageal, pancreatic, hepatocellular p16 Loss of cell-cycle control Most tumor types VHL Altered protein degradation Clear-cell renal cell carcinoma p73 Loss of cell-cycle control Leukemia, lymphoma, ovarian RASSF1A Aberrant cell transduction Lung, breast, ovarian, kidney, nasopharyngeal p15 Loss of cell-cycle control Leukemia, lymphoma, gastric, squamous cell carcinoma, hepatocellular GSTP1 Increased DNA damage Prostate
  • the methylation of sample from the same individual is determined over a period of time, e.g., days, weeks, months, or years. Determination of changes in methylation can be useful for providing diagnoses; prognoses; therapy selection; and monitoring progression for various diseases; and, in the case of cancer, tumor typing and staging. While the methods of the invention also provide for the detection of specific methylation events, the present methods are particularly notable because they are not limited by a prediction or expectation that the methylation state of a particular nucleotide is determinative of a phenotype.
  • Amplification primers can be designed to amplify loci associated with a particular phenotype or disease.
  • multiplex DNA methods can be used to amplify multiple targets from the same sample.
  • the additional targets can represent controls (e.g., from a locus of known methylation status) or additional loci associated with a phenotype or disease.
  • the methods of the invention may be used to identify new loci associated with a disease phenotype, such as cancer, or to validate such an association.
  • a number of possibilities are available for determining the relative amount of methylation at a genetic locus of interest. For example, partial or complete digestions can be performed, methylation-sensitive or methylation-dependent restriction enzymes can be used, sodium bisulfite treatment can be employed, etc. Without intending to limit the invention to a particular series of steps, the following possibilities are further exemplified.
  • a DNA sample may be digested (partially or to completion) with Mcr BC or another methyl-dependent restriction enzyme and a locus is subsequently amplified using quantitative DNA amplification (e.g., PCR, rolling circle amplification, and other methods known to those skilled in the art).
  • quantitative DNA amplification e.g., PCR, rolling circle amplification, and other methods known to those skilled in the art.
  • Kinetic profiles of amplification reactions can be obtained by numerous means known to those skilled in the art, which include fluorescence reaction monitoring of TaqManTM, Molecular BeaconsTM, SYBRGREENTM incorporation, ScorpionTM probes, LuxTM probes, and others.
  • the DNA sample may be split into equal portions and one portion is treated with the methylation-dependent restriction enzyme and the other is not.
  • the two portions are amplified and compared to determine the relative amount of methylation at the locus.
  • the DNA sample can be split into equal portions, wherein each portion is submitted to a different amount of partial digestion with Mcr BC or another methylation-dependent restriction enzyme.
  • the amount of intact locus in the various portions can be compared to a control population (either from the same sample representing uncut DNA or equivalent portions from another DNA sample).
  • the equivalent portions are from a second DNA sample
  • the second sample can have an expected or known number of methylated nucleotides (or at least methylated restriction enzyme recognition sequences) or, alternatively, the number of methylated recognition sequences can be unknown.
  • the control sample will often be from a sample of biological relevance, e.g., from a diseased or normal tissue, etc.
  • the DNA sample may be partially digested with one or more methylation-sensitive restriction enzymes and then amplified to identify intact loci. Controls in these cases are similar to those used for methylation-dependent restriction enzyme digestions described above. Untreated controls are undigested, and any treated control DNA samples are digested with methylation-sensitive restriction enzymes.
  • a sample may be separated into at least two portions.
  • the first portion is digested with an enzyme from one of the three possible methylation-sensing classes (i.e., methylation sensitive, methylation insensitive, and methylation dependent).
  • Each additional portion is digested with the isoschizomeric partner from a different methylation-sensing class from the enzyme used to digest the first portion.
  • the intact loci are then amplified and quantified.
  • the relative methylation at the locus can be determined by comparing the results obtained from any two of the reactions to each other, with or without comparison to an undigested portion. In the case where methylation insensitive enzymes are used, the portion must undergo a partial digestion.
  • the DNA sample may be treated with an agent that modifies unmethylated cytosine, but leaves methylated cytosine unmodified, e.g., sodium bisulfite.
  • the sample is separated into equal portions, and one portion is treated with a methylation-dependent restriction enzyme (e.g., Mcr BC).
  • Mcr BC methylation-dependent restriction enzyme
  • Sodium bisulfite treatment does not modify Mcr BC recognition sites because sodium bisulfite modifies unmethylated cytosine and the recognition site of each Mcr BC hemi-site is a purine base followed by a methylated cytosine.
  • Samples from both cut and uncut portions are then amplified using at least one primer that distinguishes between methylated and unmethylated nucleotides.
  • the amplified portions are then compared to determine relative methylation.
  • Certain quantitative amplification technologies employ one or more detection probes that are distinct from the amplification primers. These detection probes can also be designed to discriminate between converted methylated and unmethylated DNA.
  • the detection probes may be used in combination with a methylation-dependent restriction enzyme (e.g., McrBC).
  • McrBC methylation-dependent restriction enzyme
  • the detection probes can be used to quantify methylation density within a locus by comparing the kinetic amplification profiles between a converted Mcr BC treated sample and a converted sample that was not treated with Mcr BC.
  • the sample may be divided into equal portions and one portion is digested (partially or completely) with a methylation-dependent restriction enzyme (e.g,. Mcr BC). Both portions are then treated with sodium bisulfite and analyzed by quantitative amplification using a primer that distinguishes between converted methylated and unmethylated nucleotides. The amplification products are compared to each other as well as a standard to determine the relative methylation density.
  • a methylation-dependent restriction enzyme e.g,. Mcr BC
  • the DNA sample may be divided into portions and one portion is treated with one or more methylation-sensitive restriction enzymes.
  • the digested portion is then further subdivided and one subdivision is digested with a methylation-dependent restriction enzyme (e.g., Mcr BC).
  • Mcr BC methylation-dependent restriction enzyme
  • the various portions and subportions are then amplified and compared. Following digestion, the portions and subportions can optionally be treated with sodium bisulfite and amplified using at least one primer that distinguishes between methylated and unmethylated nucleotides.
  • the DNA sample may be divided into four portions: a first portion is left untreated, a second portion is contacted with a methylation-sensitive restriction enzyme (wherein intact sequences are methylated), a third portion is contacted with a methylation- dependent restriction enzyme (wherein intact sequences are unmethylated), and a fourth portion is contacted with a methylation-sensitive restriction enzyme and a methylation- dependent restriction enzyme in which one of the restriction enzymes in the fourth portion is contacted to the sample under conditions that allow for at least some copies of potential restriction enzyme cleavage sites in the locus to remain uncleaved (e.g., under partial digest conditions and/or using McrBC).
  • a first portion is left untreated
  • a second portion is contacted with a methylation-sensitive restriction enzyme (wherein intact sequences are methylated)
  • a third portion is contacted with a methylation- dependent restriction enzyme (wherein intact sequences are unmethylated)
  • a fourth portion is contacted with a methylation-sensitive
  • a fifth portion of the sample can be analyzed following treatment with a methylation insensitive isoschizomer of a methylation-dependent or methylation-sensitive restriction enzyme used in another portion, thereby controlling for incomplete digestions and/or mutations at the restriction enzyme recognition sequence.
  • the portions and subportions can optionally be treated with sodium bisulfite and amplified using at least one primer that distinguishes between converted methylated and unmethylated nucleotides.
  • Kits may be used for performing the methods of the invention.
  • the kits can comprise, e.g., a methylation-dependent restriction enzyme or a methylation sensitive restriction enzyme, a control DNA molecule comprising a pre-determined number of methylated nucleotides, and one or two different control oligonucleotide primers that hybridize to the control DNA molecule.
  • the kits comprise a plurality of DNA molecules comprising different pre-determined numbers of methylated nucleotides to enable the user to compare amplification of a sample to several DNAs comprising a known number of methylated nucleotides.
  • kits will often contain written instructions for using the kits.
  • the kits can also comprise reagents sufficient to support the activity of the restriction enzyme.
  • the kits can also include a thermostable DNA polymerase.
  • kits comprise one or two different target oligonucleotide primers that hybridize to a pre-determined region of human genomic DNA.
  • the primers can allow for amplification of loci associated with the development or prognosis of disease.
  • kits may comprise one or more detectably-labeled oligonucleotide probes to monitor amplification of target polynucleotides.
  • kits may comprise at least one target oligonucleotide primer that distinguishes between modified unmethylated and methylated DNA in human genomic DNA.
  • kits also typically include a fluorescent moiety that allows the kinetic profile of any amplification reaction to be acquired in real time.
  • kits may comprise at least one target oligonucleotide primer that distinguishes between modified unmethylated and methylated DNA in human genomic DNA. These kits will also typically include an agent that modifies unmethylated cytosine.
  • kits may comprise an RNA probe, a binding agent (e.g., an antibody or an antibody mimetic) that specifically binds RNA:DNA complexes, detection reagents, and methylation sensitive and/or methylation dependent restriction enzymes.
  • a binding agent e.g., an antibody or an antibody mimetic
  • the following example illustrates how the methods of the invention can be used to determine the number of methylated copies of a locus, the number of unmethylated copies of a locus, the number of hemimethylated copies of a locus, the number of mutated copies of a locus, and the total number of copies of a locus in a population of nucleic acids.
  • the nucleic acids are isolated from a sample and divided into portions, each of which contain all of the sequences present in the sample.
  • This example uses the restriction site for Sau 3A I for illustrative purposes and monitors 6mA methylation
  • different enzymes could be selected to monitor cytosine methylation.
  • Any given restriction site has three potential states: (1) hemimethylated; (2) methylated; (3) unmethylated ; and (4) mutated.
  • Sau 3A I is a methylation insensitive restriction enzyme which cuts when a methylated adenosine residue is at its recognition site.
  • Dpn I is a methylation-dependent restriction enzyme which cuts only when a methylated adenosine residue is at or near its recognition site on both strands.
  • Mbo I is a methylation-sensitive enzyme that does not cut when a methylated adenosine residue is at its recognition site, and is also the isoschizomer of Sau3 AI.
  • Hemimethylated sites are cut by Sau 3A I, but not by Dpn I or Mbo I; methylated sites are cut by Dpn I and Sau3A I, but not by Mbo I; and unmethylated sites are cut by Sau3A I and Mbo I, but not by Dpn I.
  • Human male placental DNA was obtained and was methylated in vitro using M.Sss I, which methylates cytosines (5mC) when the cytosines are followed by guanosine ( i.e ., GC motifs).
  • the resulting in vitro methylated DNA was then mixed into unmethylated male placental DNA at known ratios, thereby producing a set of mixes, each comprising a different percentage of total copies that are methylated.
  • the various mixtures were then divided into three portions: an uncut portion; a portion digested with Hha I, a methylation-sensitive restriction enzyme that is sensitive to 5mC and having the recognition sequence G C GC, where underlined nucleotides are unmethylated; and a portion digested with both Hha I and Mcr BC.
  • Mcr BC is a methylation-dependent restriction enzyme that cleaves in the proximity of its methylated recognition sequence.
  • the digested sequences were subsequently amplified using primers specific for a region upstream of the CDKN2A (p16) gene in the human genome-[Ensembl gene ID# ENSG00000147889]. This region was determined to be unmethylated in human male placental DNA that has not been methylated in vitro.
  • the primer sequences were:
  • a threshold at which the signal from the amplification products could be detected above background was determined empirically from a parallel analysis of a template dilution standard curve.
  • the threshold was adjusted to maximize the fit of the regression curve (Ct vs log [DNA]), according to standard cycle threshold determination protocols familiar to those skilled in the art, such as those described in e.g. , Fortin et al., Anal. Biochem. 289: 281-288 (2001 ).
  • the threshold was fixed and the Ct was calculated by the software (MJ Research Opticon II Monitor V2.02).
  • the derived cycle thresholds increased at higher dilutions of methylated to unmethylated DNA ( Figure 2 ).
  • cycle threshold shift can be used to accurately predict the relative proportion of copies that are methylated in the sample out of the total number of copies in the sample.
  • Figure 2 also illustrates that the addition of Hha I (a methylation sensitive restriction enzyme) and Mcr BC (a methylation-dependent restriction enzyme) further alters the Ct compared to the samples treated with Hha I alone.
  • Hha I a methylation sensitive restriction enzyme
  • Mcr BC a methylation-dependent restriction enzyme
  • Figure 3 depicts the kinetic profile of four portions at three dilution of methylated DNA to unmethylated DNA.
  • all four portions were digested first with the methylation sensitive restriction enzyme Hha I.
  • the first two portions in each dilution were digested with McrBC, and the second two portions in each dilution were untreated with regards to McrBC.
  • All portions were the amplified under identical conditions and the fluorescence intensities were measured. Three observations can be made. First, the duplicate reactions have nearly identical Ct values, demonstrating that the assays are highly reproducible.
  • Figure 3 shows the fluorescent kinetic profile of a series of portions all diluted to 1:2,000 methylated copies to unmethylated copies, respectively. While the overall fluorescence obtained from the 1:2,000 reactions is not ideal, one can see a difference between the Hha I and the Hha I/ Mcr BC reactions. Notice that the McrBC digestion destroys the accumulation of the fluorescence, and the melting point curve in Figure 4 shows a specific peak at 89° C, which is the predicted melting temperature for the 181bp specific amplicon. Here we are clearly detecting merely 1.4 cellular equivalents of methylated DNA diluted into a total of 2,762 cellular equivalents of DNA.
  • a standard sample set is generated in numerous ways. For example, a methylase (e.g ., M.Sss I or other methylases such as M.Hha I, M.Alu I) is applied in vitro to a series of DNA samples to produce a standard set of DNAs known to have increasing methylation densities.
  • This standard set is generated by first obtaining a sample of known sequence (e.g. , the locus of interest). Next, the sample is divided into a series of samples and each sample in the series is treated with the chosen methylase in the presence of magnesium and in a manner that results in increasing methylation densities of the samples in the series.
  • a partial methylation reaction refers to contacting DNA with a cocktail of one or more methylases under appropriate reaction conditions such that the methylase modifies some ( e.g. , about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%) but not all of the possible methylase recognition sites for each enzyme in the methylase cocktail.
  • a DNA sequence is partially methylated by treating DNA with an active methylase for a shorter period of time than is necessary to achieve complete methylation, and then terminating the reaction, or under other altered reaction conditions that allow for the desired amount of partial methylation.
  • the methylation densities of each sample in the series are measured by sequencing a statistically significant sample of clones from a bisulfite-treated portion of each series member in the set, by identifying the converted cytosines within each clone, and by calculating the average methylation density for each reaction within the methylation sample set.
  • the methylase acts in a stochastic manner, and not a processive manner. For M.Sss I, this is achieved by conducting the reaction in the presence of magnesium, since M. Sss I methylates DNA in a processive way in the absence of magnesium, while in the presence of magnesium, the enzyme methylates CpGs in a nonprocessive, stochastic manner.
  • DNA is collected from two sources: a test population (diseased) and a control population (normal).
  • Mcr BC Each population of DNA fragments is similarly submitted to various partial or complete digestions with the enzyme Mcr BC.
  • Mcr BC recognizes two R M C sites, each a half site, that are within 20 to 4,000 bases with an optimal separation of the half sites of 50-103 bp and then cuts the DNA fragment sometimes 3' of both half sites, sometimes 3' of the 5' most half site and 5' of the 3' most half sites, and sometimes 5' of both half sites.
  • the digested DNA in each population is amplified and the amount of the amplified locus is measured as a function of cycle number.
  • cycle number The greater the number of methylated half sites in the locus of interest on a given DNA fragment within the population studied, the greater the probability that Mcr BC will cut between the PCR primers, and, therefore, a greater number of amplification cycles will be required to achieve the identical concentration of amplified PCR locus.
  • concentration curve of amplified DNA of the test population is compared to the concentration curve of amplified DNA from the control population. Concentration curves reflect the amount of intact DNA as a function of the amount of digestion in a series of different partial digestions.
  • DNA is obtained from a single source, and is divided into two populations.
  • the first population of DNA is completely digested with the enzyme Mcr BC, while the remaining population is untreated.
  • the first population is digested with a cocktail of one or more methylation sensitive restriction enzymes (e.g ., Hpa II, Hha I, or Aci I, etc. ), while the second population of DNA is untreated.
  • the digested DNA in the first population is amplified and the amount of the amplified locus is measured as a function of cycle number.
  • a cocktail of methylation sensitive restriction enzymes is used, the greater the number of methylated restriction sites in the locus of interest on a given DNA fragment within the population studied, the lower the probability that the methylation sensitive cocktail of enzymes will cut between the PCR primers. Therefore, a lower number of amplification cycles will be required to achieve the identical concentration of amplified PCR locus.
  • a comparison is made between the kinetics of the amplification reaction profiles from the treated and untreated populations.
  • the kinetics of the amplification reaction profiles are compared to those obtained from a known in vitro generated methylation sample set, i.e ., a standard methylation curve.
  • DNA is obtained from a single source, and is divided into a series of two or more portions.
  • This series is exposed to an increasing amount of partial digestion by a methylation dependent restriction enzyme, such as Mcr BC.
  • Mcr BC methylation dependent restriction enzyme
  • the first portion of DNA fragments is untreated, the second portion is lightly digested with Mcr BC, and subsequent populations are more fully digested (but less than completely) with Mcr BC.
  • the range of partial digestions is obtained through the manipulation of reaction conditions, such as the titration of enzyme amounts, digestion times, temperatures, reactants, buffers, or other required components.
  • the DNA from the series of portions are amplified and the amount of amplified PCR loci is measured after a fixed number of cycles.
  • DNA is collected from two sources: a test population (diseased) and a control population (normal). Each population is divided into groups of two or more portions. Each group is exposed to an increasing amount of partial digestion by a methylation sensitive restriction enzyme (e.g ., Hpa II, Mbo I (A)). The first portion of DNA fragments is untreated, the second portion is lightly digested with the methylation sensitive restriction enzyme, and subsequent populations are more fully digested (but less than to completion) with the enzyme.
  • the range of partial digestions is obtained through the manipulation of reaction conditions, such as the titration of enzyme amounts, digestion times, temperatures, reactants, buffers, or other required components.
  • the second group of portions is similarly digested with an isoschizomeric partner of a different methylation-sensing class from the enzyme used to treat the first group of portions (e.g ., Msp I and Sau 3AI (A), respectively). Alternatively, the second group of portions remains untreated.
  • an isoschizomeric partner of a different methylation-sensing class from the enzyme used to treat the first group of portions (e.g ., Msp I and Sau 3AI (A), respectively).
  • the second group of portions remains untreated.
  • a comparison is made between the kinetic reaction profiles between the groups (group vs. group). Additionally, to determine whether the locus of interest between the two tissues is more or less methylated, a comparison is made between the kinetic reaction profiles between the populations (diseased groups vs. normal groups).
  • DNA is obtained from a single source and is divided into groups of two or more portions.
  • DNA is collected from two sources: a test population (diseased) and a control population (normal), and is divided into groups of two or more uniform portions.
  • the groups of uniform portions are treated with a fixed number of units of a cocktail of one of more methylation sensitive restriction enzymes (e.g ., Hpa II, Hha I, or Aci I) for varied amounts of time.
  • methylation sensitive restriction enzymes e.g ., Hpa II, Hha I, or Aci I
  • a comparison is made between the kinetic reaction profiles between the groups (group vs. group). Additionally, to determine whether the locus of interest between the two tissues is more or less methylated, a comparison is made between the kinetic reaction profiles between the populations (diseased groups vs. normal groups). Finally, the overall amount of methylation can be determined by comparing these results to those obtained from the standard sample set (see Example 3).
  • DNA is obtained from a single source and is divided into two portions. Alternatively, DNA is collected from two sources: a test population (diseased) and a control population (normal), and each population is divided into two portions.
  • one portion from each population is treated with sodium bisulfite, which converts the unmethylated cytosine residues to uracil, leaving unconverted methylated cytosine residues.
  • the bisulfite-treated portion is divided into two equal subportions.
  • one portion from each population is digested with a cocktail of one or more methylation sensitive restriction enzymes (e.g ., Hpa II, Hha I, etc .), leaving the remaining portion untreated.
  • the digested portion is similarly divided into two equal subportions.
  • One of the bisulfite-treated subportions is completely digested with the enzyme Mcr BC, while the remaining subportion is untreated.
  • one of the methylation sensitive restriction enzyme-treated subportions is completely digested with the enzyme McrBC, while the remaining subportion is untreated.
  • One or both of the amplification primers are designed to resemble the bisulfite converted sequence overlapping at least one methylated cytosine residue. In this way, only those fragments that belong to the subset of fragments that were methylated at that primer in the test population have the potential of becoming amplified, while those fragments in the subset of fragments that remained unmethylated in the locus of interest will not be amplified.
  • primers designed to the native sequence are used and only alleles that were methylated at the recognition sites remain intact and will be amplified.
  • the kinetics of the amplification reaction profiles are compared to those obtained from a known in vitro generated methylation sample set, i.e., a standard methylation curve.
  • this Example could also be performed by reversing the order of the sodium bisulfite conversion and the McrBC-digestion steps described above (i.e ., Mcr BC digestion takes place prior to sodium bisulfite conversion).
  • This example demonstrates determining the average density of methylation (i.e., the average number of methylated nucleotides) within a locus.
  • methylation i.e., the average number of methylated nucleotides
  • Figure 7 it is likely that in many diseases, methylation of one or more loci goes through a progression of increased methylation density corresponding to disease progression.
  • Previously-described methylation detection techniques involve detecting the presence or absence of methylation at one or more particular nucleotides but do not provide analysis of density across a locus.
  • the present invention provides methods for detecting the average number of methylation events within a locus.
  • This discovery works by treating a locus with a methylation-dependent or methylation-sensitive restriction enzyme under condition such that at least some copies of potential restriction enzyme cleavage sites in the locus to remain uncleaved. While these conditions can be achieved by allowing for partial digestion of a sample, the particular recognition and cutting activity of Mcr BC allows for additional options.
  • Mcr BC randomly cuts 5' or 3' of the recognized pair of half sites
  • the probability of cutting at a locus is function of the number of methylated half-sites present at or near the locus. For a set concentration of enzyme and time of incubation, the more methylation sites within a locus, the greater the probability McrBC will cut at the locus (or between the primers in the case of PCR). However, under ideal circumstances and sufficient number of DNA copies, the probability that Mcr BC will cut every copy of a locus is low because it will sometimes cut at a distance outside of the locus, thereby leaving the locus intact.
  • the number of intact loci is inversely proportional to the average number of methylated nucleotides within the locus.
  • the number of intact loci is inversely proportional to the Ct value for sample.
  • the Ct value is proportional to the average number of methylated nucleotides within a locus.
  • This example demonstrates the ability of methylation-dependent and methylation-sensitive restriction enzymes to distinguish different methylation densities at a locus.
  • a 703 bp portion of the promoter of p16 was amplified.
  • the portion was methylated in vitro in a time course with M.SssI under conditions that promote stochastic methylation.
  • the reactions were purified and each amplicon then was diluted more than 1 million fold in TE buffer, and was added back to the human genome at a ratio that should approximate a normal copy balance (i.e ., two copies per 7.9 picograms).
  • the human genome used was homozygous for a deletion of the p16 gene.
  • the deletion cell line is CRL-2610. This allowed us to add a fixed amount of the human genome ( i.e ., control for the complexity of the genome in our reaction).
  • DNA samples were cleaved with Aci I (a methylation-sensitive restriction enzyme), Mcr BC (a methylation-dependent restriction enzyme), or both as double digest, and the portion was amplified. Amplicons were detected with the MS_p16(207) SYBR green real-time PCR system. Twenty nanograms of input DNA (genome + amplicon) equal ⁇ 2764 cellular equivalents/per PCR reaction. Each set of four digests was brought up to volume in restriction salts with BSA and GTP such that it could be split into four tubes ( ⁇ 4 ⁇ g). Each of the four digest tubes ( ⁇ 1 ⁇ g) had 100 ⁇ l total volume such that 2 ⁇ l could be added to PCR reactions, thereby adding 20ng of DNA. Digests were allowed to proceed for four hours and were heat killed for 20 minutes. PCR conditions:
  • FIG. 16 Another way to visualize the data is by plotting the change in cycle threshold values ( ⁇ Ct). See, Figure 16.
  • Figure 16 displays the ⁇ Ct for Mcr BC-treated compared to untreated at each time point in the partial methylation reaction, and the corresponding ⁇ Ct for the Aci I digests ( Aci I compared to untreated).
  • the Mcr BC and Aci I ⁇ Ct lines provide an intersecting inverse pattern.
  • the Aci I graph displays a chunky shape because its cut sites are fixed, while McrBC displays a smooth continuous distribution, reflecting its ability to cut more or less randomly following site recognition. Frequency of cutting is proportional to the expected change in methylation occupancy based upon the time course.
  • the error bars associated with the real-time measurements are indicated. If they are not visualized, they are within the data point.
  • This example demonstrates the ability of the present technology to determine the methylation of a target sequence that is present in a genome more than one time (i.e., more than one copy) using an assay that monitors a sequence repeated in the kafirin gene cluster in Sorgum bicolor.
  • kafirin genes were annotated from the publicly available sequence of a BAC clone AF527808 from Sorghum bicolor .
  • PCR primers were designed to amplify a 247 bp amplicon from all 11 kafirin genes (the primer sequences were conserved in all 11).
  • Sorghum genomic DNA isolated from seedling leaf was divided into 6 equal portions. The six portions were treated in the following manner: i) untreated (mock treated), ii) HhaI digested, iii) McrBC digested, iv) HhaI and McrBC digested, v) PstI digested and, vi) PstI and McrBC digested. Equal volume aliquots from the six portions were amplified using the above PCR primers in the following manner: The SYBR green real-time PCR cycling parameters were 95° C for 3 minutes, followed by 50 cycles of 2 step PCR 95° C for 30 sec, 56° C for 30 seconds with the Dynamo Kit from MJ Research (Boston, MA). We utilized both a low temperature (70° C) and a high-temperature plate read (82° C). The input of genomic DNA was 10 ng per PCR reaction. The threshold was set using a template dilution standard control.
  • the kinetic profiles for the 6 PCR reactions are depicted in Figure 18 .
  • the inset in Figure 18 depicts the template dilution standard curve used to set the cycle threshold for the experiment. Each set of 6 digests was performed three times, and each of the 18 digests had four PCR replicates. The PCR reactions were determined to be highly reproducible.
  • the average difference in Ct between the Mcr BC single and Hha I + Mcr BC double digests is 2.46 cycles (22.08 ⁇ 0.34 Hha I + Mcr BC - 19.62 ⁇ 0.19 Mcr BC).
  • the Ct of any locus is a function of the number of copies present within the assay tube.
  • Each of the eleven genes was broken into ⁇ 1.5 kb pieces which were aligned to create a consensus kafirin assembly ( Figure 17 ). The consensus kafirin sequence was examined and PCR primers amplifying a 247 bp amplicon were selected (see above).
  • the Hha I digested (orange) sample has the same Ct as the mock treated control (red); however, the Hha I+McrBC double digest (green) has a Ct that is 2.46 cycles greater than the McrBC alone (blue), indicating that some Hha I sites must not be modified.
  • a cycle threshold difference of 2.46 indicates that there is 2 2.46 , or approximately 5.5-fold, less DNA in the Hha I+ Mcr BC double digested sample. This suggests that 2 out of the 11 kafirin genes have some unmethylated Hha I sites.
  • a 1x shotgun sequence was generated of the methyl filtered sorghum genome (See U,S. Patent Publication No. 20010046669 ), Bedell et al., PLOS in press ). 95% of the genes in the sorghum genome were determined to be represented in the methyl filtered sequence set. In the kafirin gene cluster, however, only 2 of 11 genes from BAC clone AF527808 were represented in the methyl filtered sequence set, suggesting that most or all of them may be methylated, and therefore are underrepresented in the methyl filtered sequence.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (13)

  1. Procédé de détection de la présence d'une méthylation en un certain locus au sein d'une population d'acides nucléiques, lequel procédé comporte les étapes suivantes :
    a) répartir la population d'acides nucléiques en au moins quatre parts ;
    b) mettre une première part en contact avec une enzyme de restriction sensible à la méthylation, de manière à obtenir une population qui comprend des copies non-méthylées du locus qui ont été fragmentées et des copies méthylées du locus qui sont restées intactes ;
    c) amplifier quantitativement les copies du locus restées intactes dans cette première part ;
    d) mettre une deuxième part en contact avec une enzyme de restriction dépendante de la méthylation, de manière à obtenir une population qui comprend des copies méthylées du locus qui ont été fragmentées et des copies non-méthylées du locus qui sont restées intactes ;
    e) amplifier quantitativement les copies du locus restées intactes dans cette deuxième part ;
    f) déterminer la présence d'une méthylation en ledit locus, en comparant le nombre de copies du locus intactes dans la première part et le nombre de copies du locus intactes dans la deuxième part ;
    g) amplifier quantitativement une troisième part des acides nucléiques, ce qui fait qu'on amplifie ainsi la totalité des copies du locus intactes présentes dans la population ;
    h) comparer le nombre total de copies du locus intactes avec le nombre de copies du locus intactes dans la première part et/ou le nombre de copies du locus intactes dans la deuxième part ;
    i) mettre une quatrième part des acides nucléiques en contact avec une enzyme de restriction dépendante de la méthylation et une enzyme de restriction sensible à la méthylation ;
    j) amplifier quantitativement les copies du locus restées intactes dans cette quatrième part ;
    k) et déterminer la présence d'une méthylation en ledit locus, en comparant le nombre de copies du locus intactes dans cette quatrième part avec le nombre total de copies du locus intactes dans la troisième part et/ou le nombre de copies du locus intactes dans la première part et/ou le nombre de copies du locus intactes dans la deuxième part.
  2. Procédé conforme à la revendication 1, comportant en outre les étapes suivantes :
    - mettre une cinquième part des acides nucléiques en contact avec une enzyme de restriction insensible à la méthylation ;
    - amplifier quantitativement les copies du locus restées intactes dans cette cinquième part, de manière à obtenir une population d'acides nucléiques porteurs d'une mutation au niveau du locus ;
    - établir la présence d'une mutation au niveau dudit locus, en comparant le nombre de copies du locus intactes dans cette cinquième part avec le nombre de copies du locus intactes dans la quatrième part et/ou le nombre total de copies du locus intactes dans la troisième part et/ou le nombre de copies du locus intactes dans la première part et/ou le nombre de copies du locus intactes dans la deuxième part.
  3. Procédé conforme à l'une des revendications précédentes, dans lequel ladite amplification quantitative est une amplification par PCR quantitative ou une amplification linéaire quantitative.
  4. Procédé conforme à l'une des revendications précédentes, dans lequel ladite amplification quantitative comprend le fait de surveiller le nombre de copies du locus au cours de l'amplification.
  5. Procédé conforme à la revendication 4, dans lequel le nombre de copies est surveillé en temps réel.
  6. Procédé conforme à la revendication 1, dans lequel :
    - on met les acides nucléiques en contact avec un agent qui modifie les bases cytosine non-méthylées, avant l'étape d'amplification ;
    - et l'on amplifie les copies du locus intactes avec une paire d'amorces oligonucléotidiques qui comporte au moins une amorce capable de distinguer un ADN non-méthylé modifié d'un ADN méthylé.
  7. Procédé conforme à la revendication 6, dans lequel ledit agent est du bisulfite de sodium.
  8. Procédé conforme à la revendication 1, dans lequel le site de méthylation se trouve en la position N4 d'une base cytosine présente au sein du locus.
  9. Procédé conforme à la revendication 1, dans lequel l'enzyme de restriction sensible à la méthylation est inopérante quand une base cytosine présente au sein de la séquence reconnue est méthylée en la position C5 .
  10. Procédé conforme à la revendication 1, dans lequel l'enzyme de restriction dépendante de la méthylation est l'enzyme McrBC.
  11. Procédé conforme à la revendication 1, dans lequel on compare la présence d'une méthylation au niveau dudit locus, entre des échantillons d'acide nucléique au nombre d'au moins deux.
  12. Procédé conforme à la revendication 1, dans lequel on établit la présence d'une méthylation en deux locus ou plus en effectuant les étapes suivantes :
    - amplifier quantitativement les copies d'ADN intactes en les deux locus différents, en partant d'une première part mise en contact avec une enzyme de restriction dépendante de la méthylation ;
    - amplifier quantitativement l'ADN intact en les deux locus, en partant d'une deuxième part mise en contact avec une enzyme de restriction sensible à la méthylation ;
    - et comparer les quantités de produits d'amplification pour les deux locus.
  13. Procédé conforme à la revendication 1, qui comporte en outre, avant la répartition de la population d'acides nucléiques en parts égales, le fait d'ajouter des séquences étiquettes aux extrémités des molécules d'une population d'acides nucléiques, et dans lequel
    - l'étape (c) consiste à amplifier quantitativement les copies méthylées du locus restées intactes dans la première part, à l'aide d'amorces qui font que l'amplification démarre à partir des séquences étiquettes ;
    - et l'étape (e) consiste à amplifier quantitativement les copies non-méthylées du locus restées intactes dans la deuxième part, à l'aide d'amorces qui font que l'amplification démarre à partir des séquences étiquettes.
EP04796072A 2003-10-21 2004-10-21 Fragmentation enzymatique differentielle Expired - Lifetime EP1682677B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10011859.5A EP2292795B1 (fr) 2003-10-21 2004-10-21 Fragmentation enzymatique différentielle

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51342603P 2003-10-21 2003-10-21
US56156304P 2004-04-12 2004-04-12
US56172104P 2004-04-12 2004-04-12
PCT/US2004/035012 WO2005042704A2 (fr) 2003-10-21 2004-10-21 Fragmentation enzymatique differentielle

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP10011859.5A Division EP2292795B1 (fr) 2003-10-21 2004-10-21 Fragmentation enzymatique différentielle
EP10011859.5 Division-Into 2010-09-29

Publications (3)

Publication Number Publication Date
EP1682677A2 EP1682677A2 (fr) 2006-07-26
EP1682677A4 EP1682677A4 (fr) 2007-12-19
EP1682677B1 true EP1682677B1 (fr) 2012-04-11

Family

ID=34527938

Family Applications (4)

Application Number Title Priority Date Filing Date
EP04796212A Expired - Lifetime EP1689887B1 (fr) 2003-10-21 2004-10-21 Procedes pour quantifier la densite de methylation d'un site d'adn
EP10011640.9A Expired - Lifetime EP2339024B1 (fr) 2003-10-21 2004-10-21 Procedes pour quantifier la densite de methylation d'un site d'ADN
EP10011859.5A Expired - Lifetime EP2292795B1 (fr) 2003-10-21 2004-10-21 Fragmentation enzymatique différentielle
EP04796072A Expired - Lifetime EP1682677B1 (fr) 2003-10-21 2004-10-21 Fragmentation enzymatique differentielle

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EP04796212A Expired - Lifetime EP1689887B1 (fr) 2003-10-21 2004-10-21 Procedes pour quantifier la densite de methylation d'un site d'adn
EP10011640.9A Expired - Lifetime EP2339024B1 (fr) 2003-10-21 2004-10-21 Procedes pour quantifier la densite de methylation d'un site d'ADN
EP10011859.5A Expired - Lifetime EP2292795B1 (fr) 2003-10-21 2004-10-21 Fragmentation enzymatique différentielle

Country Status (8)

Country Link
US (4) US7910296B2 (fr)
EP (4) EP1689887B1 (fr)
JP (2) JP4887154B2 (fr)
AT (2) ATE553218T1 (fr)
AU (2) AU2004284456B2 (fr)
CA (2) CA2542526C (fr)
ES (2) ES2382780T3 (fr)
WO (2) WO2005040399A2 (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1774511B (zh) * 2002-11-27 2013-08-21 斯昆诺有限公司 用于序列变异检测和发现的基于断裂的方法和系统
WO2004097369A2 (fr) * 2003-04-25 2004-11-11 Sequenom, Inc. Procedes et systemes de fragmentation et systemes de sequençage de novo
US9394565B2 (en) 2003-09-05 2016-07-19 Agena Bioscience, Inc. Allele-specific sequence variation analysis
WO2005040399A2 (fr) * 2003-10-21 2005-05-06 Orion Genomics Llc Procedes pour quantifier la densite de methylation d'un site d'adn
US7459274B2 (en) * 2004-03-02 2008-12-02 Orion Genomics Llc Differential enzymatic fragmentation by whole genome amplification
US9249456B2 (en) 2004-03-26 2016-02-02 Agena Bioscience, Inc. Base specific cleavage of methylation-specific amplification products in combination with mass analysis
US7608394B2 (en) * 2004-03-26 2009-10-27 Sequenom, Inc. Methods and compositions for phenotype identification based on nucleic acid methylation
DE602004030430D1 (de) * 2004-06-23 2011-01-20 Epigenomics Ag Verfahren zur Quantifizierung von methylierter DNS
WO2006031745A2 (fr) * 2004-09-10 2006-03-23 Sequenom, Inc. Methodes d'analyse de sequence d'acide nucleique superieure
US7820385B2 (en) * 2006-03-22 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services, Centers For Disease Control And Prevention Method for retaining methylation pattern in globally amplified DNA
US7754428B2 (en) 2006-05-03 2010-07-13 The Chinese University Of Hong Kong Fetal methylation markers
WO2008008501A2 (fr) * 2006-07-14 2008-01-17 University Of Georgia Research Foundation, Inc. Dosage du polymorphisme de la longueur des fragments de restriction inverse et utilisations de celui-ci
TWI335354B (en) * 2006-09-27 2011-01-01 Univ Hong Kong Chinese Methods for the detection of the degree of the methylation of a target dna and kits
ATE535621T1 (de) 2006-10-18 2011-12-15 Epigenomics Ag Molekül zur bereitstellung eines standards zur quantitativen analyse des methylierungsstatus einer nukleinsäure
JP2008136404A (ja) * 2006-11-30 2008-06-19 Sysmex Corp Ｄｎａメチル化検出における非メチル化シトシン変換処理後のｄｎａ量の確認方法
US8206927B2 (en) 2007-01-23 2012-06-26 Sequenom, Inc. Method for accurate assessment of DNA quality after bisulfite treatment
EP2503008B1 (fr) * 2007-04-19 2015-04-01 Molecular Detection Inc. Méthodes, compositions et kits de détection et d'analyse de bacteries resistantes aux antibiotiques
US20090181391A1 (en) * 2007-11-01 2009-07-16 Zymo Research Corporation Methods for analysis of dna methylation percentage
AU2009223671B2 (en) * 2008-03-11 2014-11-27 Sequenom, Inc. Nucleic acid-based tests for prenatal gender determination
US20090253121A1 (en) * 2008-04-04 2009-10-08 Micah Halpern Method for amt-rflp dna fingerprinting
CN102089444A (zh) 2008-05-14 2011-06-08 德玛泰克国际公司 利用核酸分析方法来诊断黑素瘤和太阳能雀斑
US8476013B2 (en) 2008-09-16 2013-07-02 Sequenom, Inc. Processes and compositions for methylation-based acid enrichment of fetal nucleic acid from a maternal sample useful for non-invasive prenatal diagnoses
US8962247B2 (en) 2008-09-16 2015-02-24 Sequenom, Inc. Processes and compositions for methylation-based enrichment of fetal nucleic acid from a maternal sample useful for non invasive prenatal diagnoses
US20120088237A1 (en) * 2009-03-09 2012-04-12 New England Biolabs, Inc. Engineering a Novel Methylation-Specific Restriction Endonuclease
US9458503B2 (en) 2009-07-02 2016-10-04 Nucleix Methods for distinguishing between natural and artificial DNA samples
EP2504448B1 (fr) * 2009-11-25 2016-10-19 Bio-Rad Laboratories, Inc. Procédés et compositions destinés à détecter un matériel génétique
US9752187B2 (en) 2009-12-11 2017-09-05 Nucleix Categorization of DNA samples
PT2510124T (pt) * 2009-12-11 2017-11-14 Nucleix Categorização de amostras de adn
WO2011132061A2 (fr) * 2010-04-20 2011-10-27 Nucleix Etablissement du profil de méthylation d'échantillons d'adn
WO2011101728A2 (fr) * 2010-02-19 2011-08-25 Nucleix Identification de source d'échantillons d'adn
WO2011087760A2 (fr) 2009-12-22 2011-07-21 Sequenom, Inc. Procédés et kits pour identifier une aneuploïdie
GB201003036D0 (en) * 2010-02-23 2010-04-07 Fermentas Uab Restriction endonucleases and their applications
EP2542698B1 (fr) 2010-03-03 2015-04-22 Zymo Research Corporation Détection de la méthylation d'adn
WO2011112845A2 (fr) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Méthodes et compositions associés à un essai de méthylation multiple pour prédire l'évolution de l'état de santé d'un patient
US20130316339A1 (en) * 2010-09-01 2013-11-28 Orion Genomics Llc Detection of nucleic acid sequences adjacent to repeated sequences
EP3940084A1 (fr) 2011-02-09 2022-01-19 Bio-Rad Laboratories, Inc. Analyse d'acides nucléiques
US12097495B2 (en) * 2011-02-18 2024-09-24 Bio-Rad Laboratories, Inc. Methods and compositions for detecting genetic material
CA2834218C (fr) 2011-04-29 2021-02-16 Sequenom, Inc. Quantification d'une minorite d'especes d'acide nucleique utilisant des oligonucleotides inhibiteurs
WO2013123481A1 (fr) 2012-02-16 2013-08-22 Cornell University Procédés et kit pour caractériser le statut de bases modifiées d'un transcriptome
ES2930180T3 (es) 2012-03-02 2022-12-07 Sequenom Inc Métodos para enriquecer ácido nucleico canceroso a partir de una muestra biológica
NZ701527A (en) 2012-05-11 2016-07-29 Clinical Genomics Pty Ltd Diagnostic gene marker panel for colorectal cancer
DK3608421T3 (da) 2012-05-18 2022-09-05 Clinical Genomics Pty Ltd Fremgangsmåde til screening for colorektal cancer
US9920361B2 (en) 2012-05-21 2018-03-20 Sequenom, Inc. Methods and compositions for analyzing nucleic acid
CA2878979C (fr) 2012-07-13 2021-09-14 Sequenom, Inc. Procedes et compositions pour enrichissement base sur la methylation en acide nucleique foetal dans un echantillon maternel, utiles pour les diagnostics prenatals non invasifs
AU2013337353B2 (en) 2012-11-02 2019-04-04 The Johns Hopkins University DNA methylation biomarkers of post-partum depression risk
WO2014168711A1 (fr) 2013-03-13 2014-10-16 Sequenom, Inc. Amorces pour analyse de la méthylation de l'adn
ES2746237T3 (es) 2013-03-14 2020-03-05 Univ Cornell Método para la cuantificación relativa de cambios en la metilación del ADN, usando reacciones combinadas de nucleasa, ligamiento, y polimerasa
EP3019630B1 (fr) 2013-07-11 2018-09-19 The Johns Hopkins University Biomarqueurs de type méthylation de l'adn et génotype spécifiques des tentatives de suicide et/ou des idées suicidaires
ES2685893T3 (es) * 2013-07-30 2018-10-15 Bgi Genomics Co., Limited Método para determinar la composición de ácidos nucleicos de una mezcla de ácidos nucleicos
CA2921234A1 (fr) * 2013-09-30 2015-04-02 Us Biomarkers, Inc. Biomarqueurs pour detecter le cancer colorectal
EP3736344A1 (fr) 2014-03-13 2020-11-11 Sequenom, Inc. Méthodes et procédés d'évaluation non invasive de variations génétiques
US9984200B2 (en) 2014-05-02 2018-05-29 Malaysian Palm Oil Board Mantle phenotype detection in palm
CN104268441B (zh) * 2014-09-23 2017-04-12 中国科学院海洋研究所 一种基于生物信息学获得双dna限制性内切酶组合的方法
US11072828B2 (en) 2014-10-06 2021-07-27 The Johns Hopkins University DNA methylation and genotype specific biomarker for predicting post-traumatic stress disorder
EP3209801B1 (fr) * 2014-10-20 2023-06-28 Commonwealth Scientific and Industrial Research Organisation Analyse de la méthylation du génome
US9984201B2 (en) 2015-01-18 2018-05-29 Youhealth Biotech, Limited Method and system for determining cancer status
US10801060B2 (en) 2015-02-24 2020-10-13 Zymo Research Corporation Assays to determine DNA methylation and DNA methylation markers of cancer
US9476100B1 (en) 2015-07-06 2016-10-25 Nucleix Ltd. Methods for diagnosing bladder cancer
WO2017136482A1 (fr) 2016-02-01 2017-08-10 The Board Of Regents Of The University Of Nebraska Procédé d'identification de caractéristiques importantes de méthylome et son utilisation
WO2017210341A1 (fr) 2016-05-31 2017-12-07 The Regents Of The University Of California Procédés d'évaluation, de surveillance et de modulation du processus de vieillissement
US10093986B2 (en) 2016-07-06 2018-10-09 Youhealth Biotech, Limited Leukemia methylation markers and uses thereof
CN107847515B (zh) 2016-07-06 2021-01-29 优美佳生物技术有限公司 实体瘤甲基化标志物及其用途
EP3481941A4 (fr) 2016-07-06 2020-04-15 Youhealth Biotech, Limited Marqueurs de méthylation du cancer du sein et de l'ovaire et leurs utilisations
CN106701939A (zh) * 2016-12-22 2017-05-24 中国热带农业科学院热带生物技术研究所 一种胞嘧啶甲基化挖掘的方法
EP3589371A4 (fr) 2017-03-02 2020-11-25 Youhealth Oncotech, Limited Marqueurs de méthylation pour diagnostiquer un carcinome hépatocellulaire et un cancer du poumon
KR102601593B1 (ko) 2017-04-19 2023-11-13 싱글레라 제노믹스, 인코포레이티드 라이브러리 제작 및 서열 분석을 위한 조성물 및 방법
EP3612627A4 (fr) * 2017-04-19 2020-12-30 Singlera Genomics, Inc. Compositions et procédés de détection de variance génomique et du statut de méthylation de l'adn
EP3655418A4 (fr) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. Procédés de traitement d'un glioblastome
EP3687501A4 (fr) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. Formulations d'iniparib et leurs utilisations
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
WO2019226648A1 (fr) 2018-05-21 2019-11-28 Battelle Memorial Institute Procédés et compositions de contrôle pour le séquençage et des analyses chimiques
SG11202103486YA (en) * 2018-10-31 2021-05-28 Guardant Health Inc Methods, compositions and systems for calibrating epigenetic partitioning assays
IL265451B (en) 2019-03-18 2020-01-30 Frumkin Dan Methods and systems for the detection of methylation changes in DNA samples
AU2020247911A1 (en) 2019-03-26 2021-11-11 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers
EP4010473A4 (fr) * 2019-08-09 2023-07-12 Battelle Memorial Institute Compositions et procédés de détection d'adn méthylé
US11427874B1 (en) * 2019-08-26 2022-08-30 Epi One Inc. Methods and systems for detection of prostate cancer by DNA methylation analysis
AU2021384324A1 (en) * 2020-11-19 2023-06-22 Nucleix Ltd. Detecting methylation changes in dna samples using restriction enzymes and high throughput sequencing
KR20220096382A (ko) * 2020-12-31 2022-07-07 주식회사 시선바이오머티리얼스 비메틸화 특이적 프로브를 이용한 유전자의 메틸화 검출 방법 및 검출 키트
CN113981046A (zh) * 2021-11-05 2022-01-28 朱运峰 一种基于定量pcr技术dna甲基化检测方法及其试剂盒
AU2023235558A1 (en) * 2022-03-15 2024-10-03 Diagenode S.A. Detection of methylation status of a dna sample
WO2024044578A1 (fr) 2022-08-22 2024-02-29 University Of Virginia Biomarqueurs de méthylation d'adn de trouble dysphorique prémenstruel et de dépression périménopausique
WO2024059649A1 (fr) 2022-09-13 2024-03-21 The Saban Research Institute; Children's Hospital Los Angeles Signature de méthylation de l'adn de rétinoblastome

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4732847A (en) 1981-06-09 1988-03-22 University Of Hawaii Monoclonal antibodies for DNA-RNA hybrid complexes and their uses
ZA853756B (en) 1984-06-01 1986-01-29 Miles Lab Nucleic acid hybridization assay employing immobilized rna probes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1291031C (fr) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Methode pour la detection de liants specifiques et des substances liables par ceux-ci
DE3803275A1 (de) 1988-02-04 1989-08-17 Dornier Medizintechnik Piezoelektrische stosswellenquelle
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6033854A (en) 1991-12-16 2000-03-07 Biotronics Corporation Quantitative PCR using blocking oligonucleotides
US5405760A (en) 1992-04-30 1995-04-11 New England Biolabs, Inc. Process for producing recombinant McrBC endonuclease and cleavage of methylated DNA
WO1995006137A1 (fr) 1993-08-27 1995-03-02 Australian Red Cross Society Detection de genes
US5552277A (en) 1994-07-19 1996-09-03 The Johns Hopkins University School Of Medicine Genetic diagnosis of prostate cancer
US5854033A (en) * 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US5871917A (en) 1996-05-31 1999-02-16 North Shore University Hospital Research Corp. Identification of differentially methylated and mutated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US5912147A (en) * 1996-10-22 1999-06-15 Health Research, Inc. Rapid means of quantitating genomic instability
US6686151B1 (en) 1998-02-06 2004-02-03 Digene Corporation Immunological detection of RNA:DNA hybrids on microarrays
GB9812768D0 (en) 1998-06-13 1998-08-12 Zeneca Ltd Methods
US7700324B1 (en) 1998-11-03 2010-04-20 The Johns Hopkins University School Of Medicine Methylated CpG island amplification (MCA)
US6312906B1 (en) * 1999-01-15 2001-11-06 Imperial College Innovations, Ltd. Immobilized nucleic acid hybridization reagent and method
GB9901072D0 (en) 1999-01-19 1999-03-10 Imp Cancer Res Tech Methods for detecting changes to a macromolecular component of a cell
US6605432B1 (en) 1999-02-05 2003-08-12 Curators Of The University Of Missouri High-throughput methods for detecting DNA methylation
US20010046669A1 (en) 1999-02-24 2001-11-29 Mccobmie William R. Genetically filtered shotgun sequencing of complex eukaryotic genomes
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US6180349B1 (en) 1999-05-18 2001-01-30 The Regents Of The University Of California Quantitative PCR method to enumerate DNA copy number
US6383754B1 (en) * 1999-08-13 2002-05-07 Yale University Binary encoded sequence tags
WO2001068807A2 (fr) 2000-03-16 2001-09-20 Fred Hutchinson Cancer Research Center Identification de sites de liaison d'adn in vivo de proteines de chromatine au moyen d'une enzyme de modification de nucleotide fixee
JP2004505612A (ja) 2000-03-31 2004-02-26 ユニバーシティ・オブ・サザン・カリフォルニア 食道腺ガンに関する後成的配列
EP1276865B1 (fr) * 2000-04-28 2014-05-21 Sangamo BioSciences, Inc. Methodes de fixation d'une molecule exogene a la chromatine cellulaire
US7439016B1 (en) 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
EP1339868A2 (fr) 2000-06-23 2003-09-03 The University of Chicago Methodes d'isolation d'adn centromere
US7300751B2 (en) 2000-06-30 2007-11-27 Syngenta Participations Ag Method for identification of genetic markers
US6498013B1 (en) * 2000-07-28 2002-12-24 The Johns Hopkins University Serial analysis of transcript expression using MmeI and long tags
CA2421102A1 (fr) 2000-08-25 2002-03-07 Lovelace Respiratory Research Institute Methode de detection de cancer par reaction de polymerisation en chaine specifique de la methylation imbriquee
CA2420840A1 (fr) * 2000-09-01 2003-02-27 Epigenomics Ag Procede de determination du degre de methylation de cytosines determinees d'adn genomique dans le contexte sequentiel 5'-cpg-3'
JP2004535757A (ja) * 2000-11-08 2004-12-02 ユニバーシティ・オブ・サザン・カリフォルニア ヘミメチル化の検出及び定量のための新規アッセイ法
US6756200B2 (en) 2001-01-26 2004-06-29 The Johns Hopkins University School Of Medicine Aberrantly methylated genes as markers of breast malignancy
US6777187B2 (en) 2001-05-02 2004-08-17 Rubicon Genomics, Inc. Genome walking by selective amplification of nick-translate DNA library and amplification from complex mixtures of templates
DE10128508A1 (de) 2001-06-14 2003-02-06 Epigenomics Ag Verfahren und Nukleinsäuren für die Differenzierung von Prostata-Tumoren
US20040197791A1 (en) 2001-06-29 2004-10-07 Makarov Vladimir L. Methods of using nick translate libraries for snp analysis
WO2003023065A1 (fr) 2001-09-06 2003-03-20 Syngenta Participations Ag Types de methylation de l'adn
US20050227230A1 (en) 2001-09-14 2005-10-13 Davies Collison Cave Detection of dna methylation
JP2006500901A (ja) 2001-09-26 2006-01-12 エピジェンクス ファーマスーティカルズ、 インコーポレイテッド Ｄｎａメチル化変化のアッセイ
WO2003035860A1 (fr) 2001-10-24 2003-05-01 The Trustees Of Columbia University In The City Of New York Methode d'identification de genes fondee sur une methylation differentielle de l'adn
DE10154318A1 (de) 2001-10-26 2003-05-15 Epigenomics Ag Verfahren zur Analyse genomischer Methylierungsmuster
AU2002359436A1 (en) * 2001-11-13 2003-06-23 Rubicon Genomics Inc. Dna amplification and sequencing using dna molecules generated by random fragmentation
US6960436B2 (en) 2002-02-06 2005-11-01 Epigenomics Ag Quantitative methylation detection in DNA samples
WO2003076666A1 (fr) 2002-03-08 2003-09-18 Naxcor Compositions et procedes de detection de la methylation d'acides nucleiques
WO2003078593A2 (fr) * 2002-03-15 2003-09-25 Epigenomics Ag Procedes de decouverte et de diagnostic utilisant glycosylase adn 5-methylcytosine
US20030175828A1 (en) 2002-03-15 2003-09-18 Lazar James G. Signal amplification by Hybrid Capture
EP1534865A4 (fr) * 2002-06-26 2005-12-21 Cold Spring Harbor Lab Procedes et compositions pour determiner des profils de methylation
US7666589B2 (en) 2002-10-02 2010-02-23 Northwestern University Methylation profile of breast cancer
US20040209299A1 (en) 2003-03-07 2004-10-21 Rubicon Genomics, Inc. In vitro DNA immortalization and whole genome amplification using libraries generated from randomly fragmented DNA
WO2005040399A2 (fr) * 2003-10-21 2005-05-06 Orion Genomics Llc Procedes pour quantifier la densite de methylation d'un site d'adn
US7459274B2 (en) * 2004-03-02 2008-12-02 Orion Genomics Llc Differential enzymatic fragmentation by whole genome amplification

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOLEMON H ET AL: "MethylScreen: DNA methylation density monitoring using quantitative PCR.", BIOTECHNIQUES NOV 2007 LNKD- PUBMED:18072598, vol. 43, no. 5, November 2007 (2007-11-01), pages 683 - 693, ISSN: 0736-6205 *
SHEIKHHA MOHAMMAD H ET AL: "High level of microsatellite instability but not hypermethylation of mismatch repair genes in therapy-related and secondary acute myeloid leukaemia and myelodysplastic syndrome.", BRITISH JOURNAL OF HAEMATOLOGY MAY 2002 LNKD- PUBMED:11972518, vol. 117, no. 2, May 2002 (2002-05-01), pages 359 - 365, ISSN: 0007-1048 *

Also Published As

Publication number Publication date
WO2005040399A3 (fr) 2005-07-21
EP1682677A4 (fr) 2007-12-19
EP1689887A2 (fr) 2006-08-16
AU2004284456A1 (en) 2005-05-06
JP2007522795A (ja) 2007-08-16
WO2005040399A2 (fr) 2005-05-06
US20050158739A1 (en) 2005-07-21
CA2542542C (fr) 2015-09-15
JP4917891B2 (ja) 2012-04-18
EP2292795B1 (fr) 2015-01-07
WO2005042704A3 (fr) 2005-06-30
AU2004286235B2 (en) 2011-05-12
JP4887154B2 (ja) 2012-02-29
AU2004284456B2 (en) 2012-04-19
US20050153316A1 (en) 2005-07-14
WO2005042704A2 (fr) 2005-05-12
JP2007512806A (ja) 2007-05-24
CA2542526C (fr) 2014-05-13
EP1689887B1 (fr) 2012-03-21
EP2339024A1 (fr) 2011-06-29
EP2292795A2 (fr) 2011-03-09
US7910296B2 (en) 2011-03-22
US20120100535A1 (en) 2012-04-26
ATE553218T1 (de) 2012-04-15
US20100240064A1 (en) 2010-09-23
US7901880B2 (en) 2011-03-08
US8163485B2 (en) 2012-04-24
EP1682677A2 (fr) 2006-07-26
CA2542526A1 (fr) 2005-05-06
ES2383970T3 (es) 2012-06-27
US8361719B2 (en) 2013-01-29
EP1689887A4 (fr) 2007-12-19
ES2382780T3 (es) 2012-06-13
EP2339024B1 (fr) 2014-12-31
AU2004286235A1 (en) 2005-05-12
CA2542542A1 (fr) 2005-05-12
ATE550438T1 (de) 2012-04-15
EP2292795A3 (fr) 2011-06-08

Similar Documents

Publication Publication Date Title
EP1682677B1 (fr) Fragmentation enzymatique differentielle
US7459274B2 (en) Differential enzymatic fragmentation by whole genome amplification
Pajares et al. Methods for analysis of specific DNA methylation status
Olkhov‐Mitsel et al. Strategies for discovery and validation of methylated and hydroxymethylated DNA biomarkers
Lorente et al. Detection of methylation in promoter sequences by melting curve analysis-based semiquantitative real time PCR
Akey et al. Assaying DNA methylation based on high-throughput melting curve approaches
JP2007125014A (ja) 遺伝子メチル化検査法対照物
WO2012031021A2 (fr) Détection améliorée de séquences d'acide nucléique adjacentes à des séquences répétées
US20080172183A1 (en) Systems and methods for methylation prediction
Awada et al. Methods for epigenomic analyses: DNA methylation
Piperi et al. DNA methylation signature analysis: how easy is it to perform?
Fraga et al. Use of PCR for DNA methylation analyses

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060509

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

A4 Supplementary search report drawn up and despatched

Effective date: 20071120

17Q First examination report despatched

Effective date: 20080225

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ORION GENOMICS, LLC

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 553218

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602004037362

Country of ref document: DE

Effective date: 20120606

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2383970

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20120627

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20120411

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 553218

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120411

LTLA Lt: lapse of european patent or patent extension
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120813

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120712

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20130114

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602004037362

Country of ref document: DE

Effective date: 20130114

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121031

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120711

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20121021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041021

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20181009

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20181018

Year of fee payment: 15

Ref country code: GB

Payment date: 20181017

Year of fee payment: 15

Ref country code: CH

Payment date: 20181015

Year of fee payment: 15

Ref country code: ES

Payment date: 20181102

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20190913

Year of fee payment: 16

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602004037362

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200501

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20191021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191021

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191021

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20210301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191022

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201031